Stockwinners Market Radar for July 22, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:36 EDT Cathie Wood's ARK Investment bought 32.8K shares of Zoom Video today

20:18 EDT Magna to acquire Veoneer for $31.25 per share in $3.8B deal - Magna (MGA) and Veoneer (VNE) announced that they have entered into a definitive merger agreement under which Magna will acquire Veoneer, a leader in automotive safety technology. Pursuant to the agreement, Magna will acquire all of the issued and outstanding shares of Veoneer for $31.25 per share in cash, representing an equity value of $3.8B, and an enterprise value of $3.3B, inclusive of Veoneer's cash, net of debt and other debt-like items as of March 31, 2021. Magna expects to operate Veoneer's Arriver sensor perception and drive policy software platform as an independent business unit, consistent with Veoneer's current practice. In addition, Magna will acquire Veoneer's leading global position in restraint control systems. Following the closing of the transaction, Veoneer will be combined with Magna's existing ADAS business and integrated into Magna's electronics operating unit. The combined business will build upon relationships with both organizations' automotive customers, suppliers and technology partners to develop best-in-class products. Magna also states that it plans to realize annual run-rate synergies of approximately $100M by 2024. These savings are incremental to Veoneer's previously announced market adjustment initiatives. The all-cash transaction will allow Magna to maintain a strong balance sheet with an expected adjusted debt to adjusted EBITDA ratio slightly above the high end of Magna's 1.0 to 1.5 target range at closing.

19:05 EDT William Penn Bancorp announces special dividend of 30c per share - The dividend is payable August 18, 2021, to common shareholders of record at the close of business on August 2, 2021.

18:05 EDT Starwood says Monmouth board rejecting Equity stock offer 'highly disappointing' - Starwood Capital Group, a global private investment firm focused on real estate and energy, issued the following statement today in response to Monmouth Real Estate Investment Corp.'s (MNR) board of directors' decision to reject an all-cash acquisition proposal from a controlled affiliate of Starwood Capital. Starwood Capital continues to believe its proposal provides substantially more value to Monmouth shareholders than its current merger agreement with Equity Commonwealth (EQC). "This latest decision of the Monmouth board to recommend the EQC stock offer is highly disappointing and we firmly believe it is not in the best interests of all of Monmouth's shareholders. The enhanced Starwood Capital proposal provides Monmouth shareholders in excess of $100 million of additional value relative to the implied value of the Equity Commonwealth transaction based on EQC's closing price today of $26.61. We believe Monmouth's shareholders will express similar disappointment when they are asked to approve the EQC transaction by a vote of two thirds of outstanding shares, and we stand ready to execute our fully financed, fully actionable all-cash offer."

17:02 EDT First Western Financial, Teton Financial sign merger agreement - First Western Financial, parent company of First Western Trust Bank, and Teton Financial Services, parent company of Rocky Mountain Bank, announced the signing of a definitive merger agreement pursuant to which Teton Financial Services would merge with and into First Western. Teton Financial Services has three branches in the state of Wyoming, assets of $420.7M, total deposits of $374.6M, and total loans of $267.9M as of June 30. Teton Financial Services also offers trust and wealth management services and had $394.1M in assets under management as of June 30. The transaction is expected to be 5.2% accretive to 2022 earnings per share and 0.4% dilutive to tangible book value, with a short tangible book value earnback period of 0.4 years. Under the terms of the merger agreement, Teton Financial Services shareholders are entitled to receive 0.0466 shares of First Western common stock and 39c in cash for each share of Teton Financial Services stock, subject to certain adjustments. Based on First Western's closing stock price on July 21, 2021, the aggregate merger consideration is valued at $47.8M. The value of the merger consideration will fluctuate until closing based on the value of First Western's stock.

17:00 EDT Four Corners Property Trust acquires Outback Steakhouse property in Florida - Four Corners Property Trust announced the acquisition of an Outback Steakhouse property for $2.3M. The property is located in a strong retail corridor in Florida and is corporate-operated under a net lease with approximately eight years of term remaining. The transaction was priced at a cap rate in range with previous FCPT transactions.

16:50 EDT Snap says saw decrease in daily time spent watching user-generated Stories - Says grew both revenue and daily active users at the highest rates in the last four years. Says laying the groundwork for an improved online shopping experience. Says next generation Spectacles are first device with a built-in 3D augmented reality display and represent another step forward toward the goal of overlaying computing on the world. Says seeing stabilization and early recovery in Story posting as some communities are reopening and reducing restrictions. Says cautiously optimistic that this will lead to increased time spent watching Stories. Says as Apple rolled-out its App Tracking Transparency-related changes near the end of Q2, the company observed higher opt-in rates than reported generally across the industry. Says continues to work with advertising partners on privacy-safe solutions and other attribution techniques.

16:39 EDT Skechers jumps 7% to $54.85 after Q2 results, FY21 guidance beat estimates

16:35 EDT Adverum Biotechnologies trading resumes

16:32 EDT Covetrus names Drew Coxhead chief accounting officer - Covetrus announced that Drew Coxhead will be appointed as vice president, corporate controller and chief accounting officer effective August 16, 2021. In this role, Coxhead will be responsible for Covetrus' global accounting function, filings with the Securities and Exchange Commission and financial reporting systems. Coxhead will replace Laura Phillips, who announced in April her intent to retire from Covetrus on August 15, 2021. "We're excited to welcome Drew to Covetrus. His track record in building and driving high-performing teams and his deep background in accounting and financial management in complex environments will complement our existing leadership well," said Matthew Foulston, Covetrus executive vice president and chief financial officer. "I look forward to working with him as we continue to drive our transformation and advance our strategic growth objectives in the years ahead."

16:29 EDT Robert Half jumps 4% to $90.25 after Q2 results beat estimates

16:28 EDT Harsco to appoint Anshooman Aga to Chief Financial Officer on August 16 - Harsco announced that Anshooman Aga will be appointed Senior Vice President and Chief Financial Officer on August 16. He will succeed Pete Minan who previously announced his planned retirement and will continue in the role of Special Advisor to the Chief Executive Officer, assisting with the transition. Mr. Aga joins Harsco from Cubic Corporation where he was the Executive Vice President and Chief Financial Officer since October 2017. In that capacity, he led all finance functions in addition to manufacturing, procurement, IT, corporate development and real estate. He was also instrumental in the completion of the May 2021 sale of Cubic to Veritas Capital and Evergreen Coast Capital Corporation, in a transaction valued at approximately $3.0B. Prior to joining Cubic, Mr. Aga was Senior Vice President and Chief Financial Officer of AECOM's multi-billion-dollar Design and Consulting Services business in the Americas. He also held a series of financial leadership positions at Siemens, including Chief Financial Officer roles for the Energy Automation business based in Nuremburg, Germany, Siemen's Rail Electrification and TurboCare. He was previously named "CFO of the Year," by the San Diego Business Journal for his exceptional financial leadership.

16:27 EDT South Plains Financial increases quarterly cash dividend to 9c per share - South Plains Financial announced that its board of directors has declared a quarterly cash dividend of 9c per share of common stock, an increase of 2c per share of common stock over the most recent quarterly cash dividend declared in April. The dividend is payable on August 16 to shareholders of record as of the close of business on August 2.

16:25 EDT Parsons joint venture awarded $567M Missile Defense Agency contract - Mobius Parsons, or MPS, a joint venture between Parsons and Mobius Consulting, was awarded a $567M contract by the Missile Defense Agency, or MDA, for the technical, engineering, advisory and management support, or TEAMS,-Next Systems Test Support contract.

16:20 EDT Robert Half CEO says 'we achieved record levels of revenues and earnings' in Q2 - "We achieved record levels of revenues and earnings in the second quarter due to a broad-based, global acceleration in demand for our staffing and business consulting services," said M. Keith Waddell, president and CEO of Robert Half. "We are particularly pleased with the strength of our permanent placement and Protiviti operations, which grew year-over-year revenues by 102 percent and 62 percent, respectively. Protiviti reached its 15th consecutive quarter of revenue gains with very strong growth in each of its solution areas." "Return on invested capital for the company was 49 percent in the second quarter," Waddell concluded.

16:17 EDT WSFS Financial reports Q2 EPS $2.01, consensus 89c - Reports Q2 tangible book value per share $28.02. Reports Q2 CET1 capital ratio 14.21%. Reports Q2 net charge-offs .23%. Rodger Levenson, chairman, president and CEO, said, "Our 2Q operating results included continued improvement across key credit metrics, solid growth in our fee businesses, and a strong capital and balance sheet position. We are well positioned for the post-COVID economic recovery, including our significant organic growth opportunity as the largest locally owned bank and wealth management franchise in the Greater Philadelphia and Delaware region."

16:14 EDT Pebblebrook Hotel acquires Jekyll Island Club Resort for $94.0M - Pebblebrook Hotel Trust "announced that it acquired the Jekyll Island Club Resort for $94.0M. The 200-room resort is listed in the National Register of Historic Places and is located in the heart of Jekyll Island, one of the renowned Golden Isles off the coast of Georgia. The Company retained Noble House Hotels & Resorts to manage the resort."

16:12 EDT ICF International awarded $49M digital communications contract by the NCI - ICF has been awarded a single-award re-compete blanket purchase agreement by The National Cancer Institute, or NCI, to provide digital communications strategy, design and implementation support for its behavioral health initiatives. The BPA will be implemented by ICF Next, ICF's marketing, communications and digital transformation agency. It has a ceiling of $49M and has a term of five years, including a one-year base and four one-year options. This work will be supported by ICF experts in smoking cessation, communications with multicultural communities and communities that are underserved, and cancer control methods, practices, and resources.

16:10 EDT Twitter CFO says performance better-than-expected across products, geographies - "We delivered better-than-expected performance across all major products and geographies while growing our audience. We continued to make significant progress on our direct response and brand products with updated ad formats, improved measurement, and better prediction. We are driving more value for advertisers with our strong push into performance-based advertising and expanded offerings for small and medium-sized businesses," said Ned Segal, Twitter's CFO.

16:09 EDT VeriSign reports 5.2% increase in .com and .net domain name registrations - The company states: "Verisign ended the second quarter of 2021 with 170.6M.com and .net domain name registrations in the domain name base, a 5.2% increase from the end of the second quarter of 2020, and a net increase of 2.59M during the second quarter of 2021. During the second quarter of 2021, Verisign processed 11.7M new domain name registrations for .com and .net, compared to 11.1M for the same quarter in 2020. The final .com and .net renewal rate for the first quarter of 2021 was 76.0% compared to 75.4% for the same quarter in 2020. Renewal rates are not fully measurable until 45 days after the end of the quarter."

16:08 EDT Twitter reports average Q2 mDAU of 206M, up from 199M last quarter - Twittter said average monetizable daily active users, or mDAU, were 206 million for Q2, compared to 186 million in the same period of the previous year and compared to 199 million in the previous quarter. Average U.S. mDAU were 37 million for Q2, compared to 36 million in the same period of the previous year and 38 million in the previous quarter. Average international mDAU were 169 million for Q2, compared to 150 million in the same period of the previous year and 162 million in the previous quarter.

16:05 EDT Intel reports Q2 CCG revenue up 6%, DCG revenue down 9% - Intel said second-quarter revenue exceeded April guidance led by continued strength in Intel's Client Computing Group, or CCG, and strong recovery in both Intel's Internet of Things Group and the Enterprise portion of its Data Center Group, or DCG. "The PC and Mobileye businesses both achieved record Q2 revenue. In the second quarter, PC platform volumes were up 33% YoY and Mobileye closed 10 additional design wins for more than 16 million total lifetime units," the company said.

16:02 EDT Ocular Therapeutix reports preliminary Q2 product revenue of $11.7M - The Company is reporting preliminary second quarter 2021 total net product revenue of approximately $11.7 million, representing a greater than 600% year-over-year increase versus the second quarter 2020 and an approximately 60% sequential increase over the first quarter of 2021. Net product revenue of DEXTENZA 0.4mg for the quarter ended June 30, 2021 is estimated to be $11.1 million, and net product revenue of ReSure(R) Sealant for the quarter ended June 30, 2021 is estimated to be $0.6 million. "We are pleased by DEXTENZA's performance in the quarter and believe that continued physician interest and more normalized cataract procedure volumes bode well for strong growth through the remainder of the year," said Antony Mattessich, President and CEO. "What gives us the greatest satisfaction however is knowing that more and more patients are enjoying a better experience following their ophthalmic surgeries."

15:44 EDT Fisker says Ocean to debut at Los Angeles Auto Show in November - In a press release last night, Fisker announced details for the first wave of its global brand experience centers. Starting in the first half of 2022, the company will open its inaugural center in Los Angeles, followed by a European center in Munich. "Fisker Brand Experience Centers will offer prospective customers the opportunity to see and experience the company's vehicles, as well as speak with product experts on hand," the company stated. Fisker added that it plans to open at least four additional centers in London, New York, Miami and Copenhagen through the second half of 2022. Fisker also announced that the Fisker Ocean will make its global debut at the upcoming 2021 LA Auto Show in November, with production starting Nov. 17, 2022. Production prototype testing will begin this year. The Fisker Ocean will enter the U.S. market at a starting MSRP of $37,499 excluding EV-related subsidies and below EUR 32,000 in Germany including taxes and EV-related subsidies. Including fleet orders from companies such as Credit Agricole Consumer Finance, Onto and Viggo, Fisker has more than 62,000 hand-raisers and 17,300 paid reservations for the Ocean. "With less than 500 days to run before we start on-time production of the Fisker Ocean, we are simultaneously focused on crafting our customer journey. Our brand experience centers will be the primary physical touchpoint for the majority of our prospective customers. Our global rollout plans are focused on the largest metropolitan areas for electric vehicle adoption - and where we can meet the greatest number of our reservation holders," said Fisker Chairman and CEO, Henrik Fisker.

15:09 EDT Northeast Community declares initial quarterly cash dividend of 6c per share - The dividend will be paid on or about August 16 to shareholders of record as of the close of business on August 2.

14:11 EDT Akamai says software update triggered bug in DNS system - Akamai Technologies said via Twitter: "At 15:46 UTC today, a software configuration update triggered a bug in the DNS system, the system that directs browsers to websites. This caused a disruption impacting availability of some customer websites. The disruption lasted up to an hour. Upon rolling back the software configuration update, the services resumed normal operations. Akamai can confirm this was not a cyberattack against Akamai's platform. We apologize for the inconvenience that resulted. We are reviewing our software update process to prevent future disruptions."

13:56 EDT EA unveils 'Dead Space' remake, 'GRID Legends' at EA Play Live - At its EA Play Live event, Electronic Arts made a number of video game announcements, including revealing racing sim "GRID Legends," which is set to launch in 2022. In addition, the company announced new content for live services games "Apex Legends" and "Knockout City," and showed new trailers for upcoming 2021 games "Lost in Random" and "Battlefield 2042," which will come with a new multiplayer tool called Portal which allows players to customize their own multiplayer modes. The big "one more thing" announcement at the end of the event, however, was for a remake of 2008 game "Dead Space," which is set to release for PC, PlayStation 5 (SONY), and Xbox Series X (MSFT).

13:15 EDT Heartland Financial raises quarterly dividend 14% to 25c per share - Heartland Financial USA announced that its board of directors approved a 14% increase in its regular quarterly cash dividend to 25c per share on the company's common stock payable on August 30, 2021, to stockholders of record at the close of business on August 16, 2021. As of June 30, 2021, there were 42,245,452 common shares outstanding listed on the NASDAQ Global Select Market under the symbol HTLF.

12:54 EDT Akamai says Edge DNS service resuming normal operations - Akamai Technologies said via Twitter regarding the issue with its Edge DNS service: "We have implemented a fix for this issue, and based on current observations, the service is resuming normal operations. We will continue to monitor to ensure that the impact has been fully mitigated."

12:51 EDT Illumina affirms commitment to re-acquire GRAIL, challenging EC's jurisdiction - Illumina affirmed its commitment to re-acquire GRAIL, a healthcare company focused on multi-cancer early detection, with Charles Dadswell, General Counsel for Illumina, stating: "This acquisition is procompetitive, and we have offered far-reaching structural and behavioral remedies to address any potential concerns. Illumina will continue to work with the European Commission to ensure that it has the information and assurances necessary to approve this transaction. We look forward to presenting our position during the Phase II process." Illumina is also challenging the EC's jurisdiction to investigate the transaction under Article 22 of the European Union Merger Regulation. "The Commission reversed decades of merger policy in asserting jurisdiction under Article 22 of the EU Merger Regulation on April 19, 2021, seven months after the deal was announced. Illumina has filed an action in the General Court of the EU seeking annulment of the EC's jurisdiction to review the acquisition," the company stated. Francis deSouza, CEO of Illumina, added: "If this acquisition does not proceed, GRAIL's European roll-out will be slower and the cost will be measured in the unnecessary loss of life. Re-uniting GRAIL with Illumina will accelerate availability of the GRAIL test by many years in the EEA and globally, saving tens of thousands of lives, and leading to significant health care cost savings."

12:36 EDT Endo reaches $35M settlement in Tennessee opioid-related case - Endo International announced that its wholly-owned subsidiaries Endo Health Solutions and Endo Pharmaceuticals have reached an agreement in principle to settle an opioid-related case in the Circuit Court for Sullivan County, Tennessee. The Staubus case involves claims by nine counties in eastern Tennessee, eighteen cities and towns within those counties and one individual plaintiff. In April, the trial court entered a default judgment on liability as a sanction for alleged discovery improprieties. A damages trial was scheduled to begin on July 26. The settlement, which remains subject to final approval by certain plaintiffs and the execution of definitive documentation, would fully and finally resolve the case in exchange for a total payment by Endo of $35M to be apportioned among all 28 plaintiffs in their discretion. The damages trial has been adjourned until August 2 to allow the remaining plaintiff approvals to be obtained. The settlement will include no admission of wrongdoing, fault or liability of any kind by Endo, who added the "settlement value should not be extrapolated to any other opioid-related cases or claims."

12:29 EDT MRMP crosses 5% threshold, sends letter to Navios Maritime Partners - MRMP-Managers LLC announced that it has transmitted a letter to Navios Maritime Partners L.P. sharing "urgent and serious concerns regarding the current management and direction of the Company." Ned Sherwood of MRMP commented, "Our group has had over thirty years of success investing in various companies that are operated by experienced multi-generation families. Angeliki Frangou is a member of a shipping family that spans generations. We are confident in her ability to manage NMM's fleet of approximately 95 dry bulk and containerships. However, we have been confused by some of her recent financial decisions - decisions which seem imprudent and illogical - that run counter to sound business principles. While we are only holders of LP interests in NMM, we have serious concerns regarding Angeliki's decisions that seem designed to benefit other entities in the Navios group. We believe these decisions run counter to her duty as Chairman & CEO of NMM. Therefore, we suggest in our letter that Angeliki and the GP implement the following policies that will benefit the unit holders of NMM and assure that we are not treated as second class holders. Set forth below is a summary of the points raised in our letter: NMM cease all ATM LP equity issuance at values less than 85% of a reasonable estimate of fleet value. In fact, NMM should begin LP share buybacks in order to take advantage of the current discounted price. If NMM continues to trade at approximately 50% or less of market value, the GP should endeavor to sell ships from their fleet to realize proceeds closer to the 100% of market value and pay down debt, buyback LP interests or distribute proceeds to LP holders. In our opinion, the current debt level at NMM is reasonable (if not below the norm) versus comparable companies, therefore, NMM's GP and management should set a distribution percentage of no less than 75% of estimated annual free cash flow. MLP's are supposed to distribute the bulk of their free cash flow to LP holders, and Angeliki Frangou's erratic policies and reluctance to distribute cash lead to uncertainty and discounted equity valuations. Given the curious behavior and policies of Angeliki Frangou as GP, we believe an independent investigation should be undertaken to determine whether the GP's actions are in any way due to conflicts of interest with other related entities. The investigation also should review ship management contracts and compare rates against other ship management entities."

12:11 EDT Mercedes-Benz to invest over EUR40B in effort to go all-electric - Daimler's Mercedes-Benz said it is getting ready to go all electric by the end of the decade, where market conditions allow. Shifting from electric-first to electric-only, the car company is accelerating toward an emissions-free and software-driven future. By 2022, Mercedes-Benz will have battery electric vehicles in all segments the company serves, the auto maker said. From 2025 onwards, all newly launched vehicle architectures will be electric-only and customers will be able to choose an all-electric alternative for every model the company makes. Mercedes-Benz intends to manage this accelerated transformation while sticking to its profitability targets. "The EV shift is picking up speed - especially in the luxury segment, where Mercedes-Benz belongs. The tipping point is getting closer and we will be ready as markets switch to electric-only by the end of this decade," said Ola Kallenius, CEO of Daimler AG and Mercedes-Benz AG. "This step marks a profound reallocation of capital. By managing this faster transformation while safeguarding our profitability targets, we will ensure the enduring success of Mercedes-Benz. Thanks to our highly qualified and motivated workforce, I am convinced that we will be successful in this exciting new era." To facilitate this shift, Mercedes-Benz is unveiling a comprehensive plan which includes significantly accelerating R&D. In total, investments into battery electric vehicles between 2022 and 2030 will amount to over EUR40B. Accelerating and advancing the EV portfolio plan will bring forward the tipping point for EV adoption. Reference Link

12:04 EDT Synlogic publishes data demonstrating potential of SYNB1618 for treatment of PKU - Synlogic announced the publication of two papers in the journals Nature Metabolism and Communications Biology. The publications detail findings from a first-in-human study of investigational Synthetic Biotic medicine SYNB1618 and the development of a mechanistic model to predict the function of an engineered bacterial therapeutic in healthy volunteers and Phenylketonuria patients. These data add to the growing body of scientific research demonstrating the therapeutic potential of Synthetic Biotic medicines for the treatment of PKU. "Our orally administered Synthetic Biotic medicines are intended to address the needs of PKU patients of all ages and disease types through the consumption of phenylalanine in the gastrointestinal tract. With two Phe-consuming strains now in the clinic, and a proof-of-concept readout in SYNB1618 anticipated in the second half of 2021, we look forward to advancing our PKU pipeline and developing a meaningful treatment for those living with PKU," said Aoife Brennan, M.B. Ch.B., Synlogic's President and CEO. Key findings from the Nature Metabolism paper entitled, "Safety and pharmacodynamics of an engineered E. coli Nissle for the treatment of phenylketonuria: a first-in-human Phase 1/2a study": In this first-in-human study of a frozen liquid formulation of SYNB1618 in healthy volunteers and patients with PKU, SYNB1618 was safe and well tolerated, with no systemic toxicity and no evidence of colonization. SYNB1618 was cleared within four days of the last dose. Dose-responsive increases in strain-specific Phe metabolites in plasma and urine were observed, demonstrating SYNB1618 is able to consume Phe and convert it to non-toxic metabolites in the GI tract of both healthy volunteers and patients with PKU. These data demonstrate the potential to use engineered bacteria in the treatment of rare metabolic disorders through the consumption of toxic substances in the GI tract.

12:00 EDT PBF Energy falls -9.3% - PBF Energy is down -9.3%, or -97c to $9.49.

12:00 EDT Daqo New Energy falls -12.6% - Daqo New Energy is down -12.6%, or -$10.03 to $69.35.

12:00 EDT Domino's Pizza rises 10.9% - Domino's Pizza is up 10.9%, or $51.18 to $521.55.

11:27 EDT Achieve Life Sciences awarded grant from NIH for cytisinicline study - Achieve Life Sciences announced earlier that it has been awarded a grant from the National Institute on Drug Abuse of the National Institutes of Health, or NIH, to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use. "This initial grant award, to commence on August 1, 2021, will be utilized to complete critical regulatory and clinical operational activities, such as protocol finalization, clinical trial site identification, and submission of a new IND to FDA for investigating cytisinicline in nicotine e-cigarette users. Upon completion of these milestones, as assessed by NIH, Achieve expects to receive the next stage of the grant award that will enable initiation of the Phase 2 ORCA-V1 clinical study evaluating cytisinicline in approximately 150 adult nicotine e-cigarette users in the United States," the company said. Achieve recently announced completion of enrollment in the Phase 3 ORCA-2 clinical trial, evaluating cytisinicline as a treatment for combustible cigarette cessation. Topline results from the ORCA-2 trial are expected in the first half of 2022.

10:33 EDT U.S. Gold says CK Gold project development on schedule - U.S. Gold Corp. announced that Kevin Francis has joined the company as Vice President - Exploration and Technical Services. Coinciding with Mr. Francis joining the company, Ken Coleman, Chief Geologist, has resigned "to pursue other opportunities that have been pending for some time," the company said. U.S. Gold stated: "To maintain the independent 'Qualified Person' review of the prefeasibility study, or PFS, resource and reserve statement, a function previously envisioned for Mr. Francis through his association with Gustavson Associates, a new independent QP is now completing a review of the work performed at the CK Gold Project to date. Subject to the completion of the review and recommendations, publication of the PFS will incur a slight delay beyond its mid-year target and is now expected in the third quarter. However, the company anticipates that the delay in the PFS will in no way effect the project's development schedule. Field work and data collection aimed at augmenting the data to be published in the PFS in the coming weeks is already underway. The objective of the 2021 field season work is to capture sufficient data to both complete Project permit applications and to close gaps in the data set to enable a feasibility study to be completed in early 2022. Additionally, the company is evaluating the potential incremental economic contribution from selling non-mineralized material as potential aggregate. Further studies are ongoing, and details will be provided as they become available."

10:25 EDT Freeport McMoRan says recent pullback in copper hasn't altered favorable outlook - Says committed to achieving Copper Mark at all copper producing sites. Says copper is critical in every aspect of achieving low-carbon goals for a green economy. Says will add significantly to future demand for copper. Says Freeport is well positioned as leading copper producer. Says demand growth is inevitable. Says assets are extremely valuable in today's world and will become more valuable. Says a significant number of workers have received vaccines. Says looks forward to continuing long-term success at Grasberg. Says expanding mine production at Lone Star. Evaluating expansion of Lone Stars' oxide ores. Says advancing plans for ESG project to recycle electronic material in Spain. Says has major opportunity for Lone Star to become cornerstone asset. Says progressing opportunities in leach technologies. Says engaged in multiple studies using a range of technologies.

10:11 EDT Cleveland-Cliffs: Set for 'monumental' debt reduction during 2H21

10:10 EDT Freeport McMoRan says Grasberg underground ramp-up proceeding 'on schedule' - Says had a strong second quarter. Says results benefited from strong pricing. Says operating cash flow generation was extremely strong. Says enthusiastic about outlook. Says teams are working safely, remains diligent with COVID-19 protocols. Says restoring some COVID-19 protocols that were previously loosened. Says team in Indonesia is doing remarkable work. Says production in the U.S. is increasing. Says encouraged about future growth in the U.S. Says generating significant cash flows which will be sustainable. Says reached debt target several months earlier than forecast. Says positioned for increasing cash returns to shareholders and investments in future organic growth. Says committed to sustainability initiatives. Comments taken from Q2 conference call.

10:09 EDT Correct: Cleveland-Cliffs sees Q3 adjusted EBITDA $1.8B, free cash flow $1.4B - Goncalves concluded: "Our team has done a remarkable job in meeting the demand for steel we have been experiencing over the past six months, overcoming the impact of the automotive chip shortage as well as limited rail and truck availability. Steel demand remains excellent and, as we continue to negotiate our contract businesses with several clients in different sectors, it is progressively translating into substantially higher contract prices later this year and into 2022. Ultimately, we are set for a monumental debt reduction during the back half of this year, and the achievement of zero net debt in 2022."

10:04 EDT EMA: Guillain-Barre syndrome 'very rare side effect' of Covid Vaccine Janssen - Guillain-Barre syndrome will be listed as a very rare side effect of COVID-19 Vaccine Janssen (JNJ) and a warning will be included in the product information to raise awareness among healthcare professionals and people taking the vaccine, the EMA said in a statement. EMA's safety committee, PRAC, assessed the available evidence, including cases reported to the European database for suspected side effects and information from scientific literature. PRAC looked at 108 cases of GBS reported worldwide as of 30 June, when over 21 million people had received the vaccine. There was one reported death among these reports. After assessing the available data, PRAC considered that a causal relationship between COVID-19 Vaccine Janssen and GBS is possible. EMA confirms that the benefits of COVID-19 Vaccine Janssen continue to outweigh the risks of the vaccine. A review of GBS cases has also taken place recently for Vaxzevria -- previously COVID-19 Vaccine AstraZeneca (AZN). The product information of Vaxzevria now includes a warning on GBS and PRAC continues to closely monitor this issue. Reference Link

10:02 EDT Gores Holdings VI, Matterport announce closing of business combination - Matterport, a spatial data company "driving the digital transformation of the built world," and Gores Holdings VI (GHVI), a special purpose acquisition company sponsored by an affiliate of The Gores Group, announced the completion of their previously announced business combination. The combined company will be named Matterport and will commence trading on Nasdaq under the new ticker symbol "MTTR" on July 23. The business combination was approved at a special meeting of Gores Holdings VI stockholders on July 20. RJ Pittman, CEO and Chairman of the Board of Directors of the combined company, said, "We're at the dawn of a new era for what's possible when buildings become data. To capitalize on this extraordinary market opportunity, we plan to increase our investment in our customers' success, scale innovation and R&D, and accelerate growth through our spatial data platform for the 20 billion spaces around the world."

10:00 EDT X Financial falls -7.0% - X Financial is down -7.0%, or -68c to $9.02.

10:00 EDT North American Construction rises 7.7% - North American Construction is up 7.7%, or $1.07 to $15.01.

10:00 EDT Studio City rises 72.0% - Studio City is up 72.0%, or $9.33 to $22.28.

09:59 EDT Commerzbank sees EUR 200M write-off in Q2 for end of project - Commerzbank said its Board of Managing Directors decided to end the project for outsourcing securities settlement to HSBC Transaction Services GmbH with immediate effect. The reasons for the decision are "technical implementation risks and changed market conditions." Due to the project stop, Commerzbank is anticipating an exceptional write-off of around EUR 200M in Q2. The write-off will not impact the liquidity or the common equity tier 1 capital of the bank, it added. Furthermore, provisions in the double-digit millions will be set aside, it said. This year's cost target of EUR 6.5B "remains valid in operational terms. However, the expenses for the exceptional write-off come in addition." The company said, "With this step, Commerzbank reduces complexity in its transformation and will firstly continue to modernise its own system landscape. The IT delivery organisation of Commerzbank introduced two years ago will make an important contribution to this. As part of its strategy 2024, the Bank has created a dedicated Key Area for Securities & Brokerage."

09:47 EDT Vislink says new products released in 2021 surpass $6M in initial sales - Vislink is pleased to announce that three new products released in 2021 have surpassed $6M in initial sales this year, exceeding company forecasts. The products, which include IP Link 3.0, Quantum Receiver and DVE 6100, were all launched in the first quarter of this year.

09:47 EDT N-able falls -7.6% - N-able is down -7.6%, or -$1.01 to $12.30.

09:47 EDT Ranger Energy rises 8.4% - Ranger Energy is up 8.4%, or 68c to $8.82.

09:47 EDT SOS Limited rises 12.8% - SOS Limited is up 12.8%, or 35c to $3.08.

09:46 EDT FirstEnergy issues statement following settlement of DOJ probe - In accordance with its obligations under the previously announced deferred prosecution agreement with the U.S. Attorney's Office for the Southern District of Ohio to resolve the Department of Justice investigation, FirstEnergy issued a statement: "Central to FirstEnergy Corp.'s effort to influence the legislative process in Ohio was the use of 501(c)(4) corporate entities. FirstEnergy Corp. used the 501(c)(4) corporate form as a mechanism to conceal payments for the benefit of public officials and in return for official action. FirstEnergy Corp. used 501(c)(4) entities in this way because the law does not require disclosure of donors to a 501(c)(4) and there is no ceiling that limits the amount of expenditures that can be paid to a 501(c)(4) entity for the purpose of influencing the legislative process. This effort would not have been possible, both in the nature and volume of money provided, without the use of a 501(c)(4) entity."

09:40 EDT Freeport McMoRan sees copper volume growth of 20% in 2021 vs. 2020 - In presentation slides for its Q2 earnings call, Freeport McMoRan said it sees copper volume growth of approximately 20% in 2021 vs. 2020 and sees gold volume growth of approximately 55% in 2021 vs. 2020. Freeport sees copper volume growth of approximately 15% in 2022 vs. 2021 and sees gold volume growth of approximately 20% in 2022 vs. 2021. Freeport sees 2021 consolidated copper sales of 3.85B lbs, consolidated gold sales of 1.3M ozs and 2021 consolidated molybdenum sales of 86M lbs.

09:36 EDT Grubhub becomes official food delivery partner of Concacaf Gold Cup - Grubhub announced a partnership to become the official food delivery partner of the 2021 Concacaf Gold Cup. "As professional soccer continues to see exponential growth, the deal with the region's premier men's national team international soccer tournament represents Grubhub's first foray into a major sports partnership," the company said in a statement. Grubhub is part of Just Eat Takeaway.com.

09:32 EDT PAVmed's Lucid Diagnostics launches partnership with UpScriptHealth - PAVmed announced that its major subsidiary Lucid Diagnostics has entered into a definitive agreement with UpScriptHealth. Pursuant to the agreement, UpScript will support Lucid's upcoming EsoGuard Telemedicine Program by providing a Lucid-branded web-based telemedicine platform for patients with chronic heartburn symptoms to request video evaluation by a physician and, if clinically indicated, referral for Lucid's EsoGuard Esophageal DNA Test.

09:31 EDT Lixte Biotechnology comment on preclinical research on LB-100, dwarfism - Lixte Biotechnology commented on pre-clinical research demonstrating that inhibition of protein phosphatase 2A with LB-100 combined with the experimental drug, vosoritide, was even more effective than vosorotide alone in stimulating bone length and cartilage area in a mouse model of the most common form of dwarfism, achondroplasia. In clinical trials, the BioMarin compound alone was beneficial. But the fact that the addition of LB-100 enhanced the activity of vosoritide in the animal models of ACH led the authors to conclude that their study provides a proof of concept that a phosphatase inhibitor may be a beneficial addition to therapy with vosoritide. Lixte CEO, John Kovach MD, commented "Our development of LB-100 as the only presently available PP2A inhibitor in clinical trials has opened a multitude of possibilities for adding inhibition of PP2A to therapeutic regimens for a range of serious diseases. LB-100 has been shown to enhance anti-cancer activity of standard chemotherapy and immunotherapy regimens against a broad spectrum of human cancers in animal models. Our focus is to demonstrate the clinical therapeutic benefit of LB-100 in one or more cancers for which more effective treatments are urgently needed. We are concentrating on small cell lung cancer and advanced soft tissue sarcomas. Many investigators of which Shuhaibar and colleagues are among the most recent have used LB-100 in pre-clinical studies that have revealed targeting of PP2A function appears to have a multitude of potential applications to serious human diseases in addition to cancer."

09:29 EDT Adamas Pharmaceuticals announces issuance of new patents for Gocovri, ADS-4101 - Adamas Pharmaceuticals announced the issuance of two patents covering Gocovri extended-release capsules: U.S. Patent No. 11,065,213 and U.S. Patent No. 11,077,073, projected to issue on August 3. These two patents are the first issued in this patent family and provide additional claims covering the drug product Gocovri, the company's medicine approved as the first and only drug to treat both dyskinesia and OFF motor complications in Parkinson's patients, and methods of using Gocovri. In addition to these two new patents for Gocovri, Adamas recently received a new patent covering ADS-4101, its investigational drug candidate being considered for partnering opportunities. This patent, which follows two recently announced U.S. patents for ADS-4101, has been issued in Japan and is the first granted in a major market country outside the U.S.

09:27 EDT 22nd Century secures new contract manufacturing agreements - 22nd Century Group announced that it has secured a substantial new agreement with a prominent tobacco industry partner that specializes in exporting cigarettes to countries outside the United States. As a result, the Company will make investments to optimize margins and improve efficiencies by hiring additional staff at its tobacco manufacturing facility in North Carolina, and by installing new equipment at the site to increase efficiencies. 22nd Century will also leverage this new relationship and others through its contract manufacturing operations to establish additional distribution channels in preparation for the launch of its VLN reduced nicotine content cigarettes. This is the latest win for 22nd Century's CMO operations. Earlier this year, the Company signed on a new cigar contract manufacturing customer, and it is currently in advanced negotiations with two other significant tobacco industry partners that could further expand 22nd Century's sales domestically and internationally. 22nd Century is focused on preparing for the launch of its VLN cigarettes, and the Company will leverage these newly established trade relationships to expand distribution of VLN after the cigarettes are introduced. In addition to the planned installation of new equipment to reduce waste at its manufacturing facility, the Company recently completed an expansion of testing capabilities at the site, which will allow for rapid, in-house analysis of its tobacco. This will improve the production cost per VLN sample by more than 90%, while significantly reducing the lead time to uncover key data. Internal testing of the VLN leaf is scheduled to begin at the facility in August, using the newly installed testing equipment. The Company is highly confident that it is in the final stages of the FDA's application process to obtain MRTP designation for its VLN cigarettes. The FDA has already authorized 22nd Century's RNC tobacco technology under the Premarket Tobacco Product Application pathway, saying that it is "appropriate for the protection of public health," and concluding that it offers, "among several key considerations, the potential to reduce nicotine dependence in addicted adult smokers, who may also benefit from decreasing nicotine exposure and cigarette consumption." MRTP designation will allow 22nd Century to communicate and market the key features of its RNC cigarettes, including the headline claim of 95% less nicotine. Although VLN contains just 0.5 milligrams of nicotine per gram of tobacco, the cigarettes taste, smell, and smoke like traditional cigarettes. The Company is fully prepared to launch its VLN cigarettes within 90 days of receiving authorization.

09:22 EDT Abbott expects base underlying business to grow 'low double digits' for 2H21

09:19 EDT GenTech closes acquisition of 'Nature Soothie' - GenTech Holdings is pleased to announce that it has closed on the agreement for the acquisition of a 75% controlling stake in Nature Spoon, the producer of Nature Soothie branded herbal supplement lollipops for children. Nature Soothie products are currently distributed through UNFI and sold in top health food stores in the United States, including Sprouts Farmer's Market and Whole Foods Market. Nature Soothie products are also sold online at NatureSoothie.com and at the Nature Soothie Amazon store. The products offer a variety of children's herbal supplements designed to address specific everyday health needs. The lollipops are made with 100% natural ingredients, including organic honey and herbal extracts such as chamomile, peppermint, black elderberry, and passionflower. All Nature Soothie products have a simple but delicious taste with only 4g of natural sugar. They are also gluten-free and contain no artificial colors, flavors, or preservatives.

09:19 EDT Exfo board will not pursue non-biding proposal from Viavi - Exfo (EXFO), acting on the unanimous recommendation of the special committee of the Board of Directors comprised entirely of independent directors, issued a statement to clarify the situation for stakeholders about the unsolicited non-binding proposal made by Viavi Solutions (VIAV) on July 20. In a going-private transaction announcement on June 7, Germain Lamonde, who controls, directly or indirectly, 61.46% of the issued and outstanding shares of Exfo and 93.53% of the voting rights attached to all the issued and outstanding shares of Exfo, stated that he would not consider any proposal made by Viavi Solutions or any alternative change of control transaction. The statements by the controlling shareholder that he rejects the Proposal led Exfo's board of directors to conclude that it will not pursue the proposal as it is not capable of being completed and therefore, is not a "Superior Proposal". The special meeting of the shareholders to approve the going-private transaction is scheduled to be held on August 13.

09:17 EDT Draganfly to complete listing of common shares on Nasdaq under DPRO - Draganfly announced that it expects to complete a listing of its common shares on The Nasdaq Capital Market in the United States under the ticker "DPRO", subject to meeting the final listing requirements of the Nasdaq. Draganfly has filed a preliminary prospectus supplement to its short form base shelf prospectus dated July 14, 2021 in connection with a proposed public offering of its common shares in the United States. Trading of the Draganfly's common shares is expected to commence on the Nasdaq subject to Draganfly satisfying the remaining conditions to list such shares on the Nasdaq.

09:16 EDT Exfo Meridian board will not pursue non-biding proposal from Viavi - Exfo (EXFO), acting on the unanimous recommendation of the special committee of the Board of Directors comprised entirely of independent directors, issued a statement to clarify the situation for stakeholders about the unsolicited non-binding proposal made by Viavi Solutions (VIAV) on July 20. In a going-private transaction announcement on June 7, Lamonde, who controls, directly or indirectly, 61.46% of the issued and outstanding shares of Exfo and 93.53% of the voting rights attached to all the issued and outstanding shares of Exfo, stated that he would not consider any proposal made by Viavi Solutions or any alternative change of control transaction. The statements by the Controlling Shareholder that he rejects the Proposal led Exfo's Board of Directors to conclude that it will not pursue the Proposal as it is not capable of being completed and therefore, is not a "Superior Proposal". The special meeting of the shareholders to approve the going-private transaction is scheduled to be held on August 13.

09:14 EDT SL Green Realty announces sale of 49% interest in 220 East 42nd Street - SL Green Realty announced that it has sold a 49% interest in 220 East 42nd Street to a real estate fund managed by Meritz Alternative Investment Management for gross consideration of $790.1M. SL Green retained a 51% interest in the property and will continue to oversee management and leasing of the building. The transaction generated net cash proceeds to SL Green of $136.1M. "This transaction demonstrates the continued global demand for core New York City office properties, particularly those that are well leased on a long-term basis to credit tenants," said Harrison Sitomer, Senior Vice President of SL Green. "With the new joint venture, 220 East 42nd Street will continue to provide SL Green shareholders with steady contractual cash flow. We are thrilled to be partnering again with Meritz on this historic asset."

09:12 EDT Abbott says achieved 'strong growth' across all four businesses in Q2 - Says new product pipeline continues to be "incredibly productive." Comments taken from Q2 earnings conference call.

09:11 EDT Rackspace Technology sees Q2 bookings $258M - In addition, the company expects second quarter bookings to be approximately $258 million, an increase of 6% compared to the first quarter of 2021.

09:11 EDT WWE and Iconic Events Releasing team to bring 'SummerSlam' to movie theaters - WWE and Iconic Events Releasing announced a new partnership that brings SummerSlam, WWE's biggest event of 2021, to movie theaters nationwide for the first time. The event will air live on Saturday, August 21 at 8 pm ET/5 pm PT and will be one of the first sporting events held at full capacity at Allegiant Stadium, and the first time it will be held at an NFL venue. "Iconic Events Releasing is proud to be in partnership with WWE to bring their incredible brand to movie theaters coast to coast," said Iconic CEO Steve Bunnell. "SummerSlam is a marquee event that demands to be seen on the big screen, with big sound, in an auditorium full of excited fans." Iconic Events Releasing brings live and filmed entertainment of all types to movie theaters as special limited engagement events, so that fans can gather together to watch their favorites on the big screen. Programming includes live pay-per-view sports, music and comedy specials, stand-up comedy events, award-winning television specials, Broadway productions, exciting holiday specials, family events, live events for album releases, rock concerts, and music docs that celebrate diversity. Iconic's national theater network represents the country's preeminent cinemas offering enhanced guest experiences, high-quality food & beverage service, and reserved seating to ensure families can enjoy a night out watching SummerSlam live in their local movie theater.

09:10 EDT GeoVax Labs announces presentation on Sudan Ebolavirus vaccine data - GeoVax Labs announced the presentation of data from a study of its preventive vaccine against Sudan Ebolavirus. The presentation was titled "A single immunization of guinea pigs with a modified vaccinia Ankara virus producing Sudan virus-like particles protects from Sudan virus lethal challenge." In her talk, Dr. Malherbe discussed the preclinical efficacy studies of GeoVax's vaccine, a novel vaccine candidate for SUDV constructed on an MVA vector expressing two immunogens derived from the Sudan virus. Upon vaccination, these immunogens form Virus Like Particles in the host, which in turn induce immunity against subsequent infections with SUDV. Immunogenicity and efficacy of MVA-SUDV-VLP were tested in a guinea pig lethal challenge model, in which a single intramuscular dose of the GeoVax vaccine protected 100% of animals challenged with a lethal dose of SUDV. A comparison between prime and prime-boost vaccinations of guinea pigs with MVA-SUDV-VLP showed that both regimens elicited SUDV-specific binding and neutralizing antibody responses, and that the second immunization enhanced these responses. Challenge of vaccinated animals with guinea pig-adapted SUDV demonstrated a complete protection against death and disease by the prime and the prime-boost regimens. Importantly, there was no difference in outcomes between the prime and the prime-boost vaccine regimens thus demonstrating the efficacy of a single dose of MVA-SUDV-VLP. This is the first report that a replication-deficient MVA vector may confer full protection against SUDV after a single dose.

09:09 EDT Rackspace Technology to invest $65M-$75M in growth businesses - Rackspace Technology announced an expected $65-$70 million of new investments designed to closely align the company's resources with fast-growing product and service offerings. The investments will enable acceleration of growth initiatives while also providing the company with a more flexible and scalable expense structure. These new investments will be targeted toward cloud services that are expected to continue to accelerate in the coming years, including cloud migration, Elastic Engineering, cloud native application development, Data/Artificial Intelligence/Machine Learning, and security services. The investments will include new service development efforts, additional delivery capabilities, go-to-market enhancements, and expansion of best-shoring centers of excellence. In addition, Rackspace Technology will expand its internal training programs to develop expertise in Cloud Engineering, Data Engineering, and Cloud Native Software Engineering. This will prepare existing employees to meet high-demand roles on the company's fast-growing professional services and Elastic Engineering teams. The investments will be funded with an estimated $95-$100 million of gross cost savings as a result of enhanced automation as well as restructuring programs to realign resources from mature and declining areas of the market, accelerate best shoring initiatives, and reduce general and administrative expenses. The 2021 impact of these actions is fully embedded in the company's quarterly and annual financial guidance. Restructuring program implementation is expected to result in total pre-tax charges of approximately $70 million to $80 million in the next 12-24 months.

09:08 EDT Infrastructure and Energy Alternatives awarded ash removal contract by Dominion - Infrastructure and Energy Alternatives (IEA) announced that the company has been awarded the Chesterfield Coal Ash Removal contract at the Chesterfield Power Station in Virginia. Dominion Energy (D) awarded this project to Saiia Construction, a subsidiary of IEA that specializes in industrial heavy civil construction for the power generation, aggregate mining, and pulp and paper sectors. Legislation passed during the 2019 Virginia General Assembly requires Dominion Energy to remove all coal ash totaling approximately 15M cubic yards at the Chesterfield Power Station. The coal ash must be recycled or placed in a lined landfill meeting federal coal ash residual and Virginia CCR regulations. Saiia Construction has been tasked with the closure of the Upper and Lower Ash Ponds at Chesterfield. Work began this past May and is expected to take approximately 13 years to complete. Saiia Construction will self-perform a full range of services from the hauling and management of conditioned CCR onsite to landfill maintenance and the full closure of the plant's impoundments. It is anticipated that at least seven million cubic yards of CCR will be recycled, while the remaining material will be stored in the station's state-of-the-art lined landfill.

09:07 EDT HP Enterprise partners with Iceotope Technologies for extreme liquid cooling - Hewlett Packard Enterprise announced an OEM agreement with Iceotope Technologies, a provider of precision immersion cooling, to offer its liquid-cooled chassis with HPE ProLiant servers in its Ku:l Extreme Data Centre solution. The combined solution runs in enterprise data centers as well as at the extreme edge aiming to provide reliable performance and efficiency while ensuring protection required for harsh edge environments. Ku:l Extreme is a Micro Data Centre solution for distributing enterprise-grade computing to extreme edge environments providing zero-touch operation with Out of Band Management offering.

09:05 EDT Proterra technology to power Taylor Machine Works next-generation equipment - Proterra and Taylor Machine Works announced a new partnership to power Taylor's next-generation ZLC-series electric container handler and ZH-series electric forklift using Proterra's industry-leading battery technology. Proterra will supply battery technology to power Taylor's next-generation material handling equipment, and the two companies will collaborate on strategies to deliver charging and infrastructure solutions to help ports and other customers electrify their heavy-duty, material handling machinery. The first Proterra Powered, next-generation Taylor ZLC-series and ZH-series machines are expected to be delivered to customers beginning in 2022. The collaboration represents Proterra's entry into the heavy-duty, material handling equipment market.

09:04 EDT Mr. Cooper names Shawn Stone EVP Chief Revenue Officer - Mr. Cooper Group announced two additions to the executive leadership team as the company focuses on becoming the largest home loan company in the country, with a customer-centric culture and best-in-class digital tools. Shawn Stone was named Executive Vice President and Chief Revenue Officer and will focus on the company's accelerated growth strategy, exploring new delivery channels and finding more ways to leverage Mr. Cooper's technologies to deliver experiences that delight customers. In his role, Stone will also lead the Mr. Cooper Originations business. Additionally, Jay Jones was promoted to Executive Vice President, leading the company's industry leading Servicing business. Jones joined Mr. Cooper in July 2019, most recently serving as Senior Vice President of Servicing. He has more than 25 years of experience in the mortgage industry and has held various key leadership roles, strategically guiding mortgage servicers through the ever-changing industry landscape. Before joining Mr. Cooper, Jones served as Executive Vice

09:03 EDT AgriFORCE appoints Troy McClellan as president, AgriFORCE Solutions - AgriFORCE Growing Systems announced that it has promoted Troy McClellan to President of the AgriFORCE Solutions division. In his new role, Mr. McClellan will be responsible for leading the commercial development strategy, with a focus on leveraging AgriFORCE IP and solutions across multiple divisions, vertical markets, and regions. In addition, he will help oversee the Company's Merger and Acqusition strategy, with a focus on identifying companies and technologies that can be leveraged within the Company's automated growing system and facility design, as well as additional business lines that leverage the Company's core agricultural and technological expertise. He will work closely with the leadership team to drive growth in the Company's emerging IP and solutions business, as well as spearhead the Company's operations and research and development efforts. McClellan has successfully led the team in the design and development of AgriFORCE growing facilities, systems, operations, IP, and breakthrough technologies as the Company's Vice President of Design and Construction.

09:03 EDT General Electric taps Dell Technologies to simplify global IT operations - Dell Technologies (DELL) and GE (GE) are extending their relationship to assist the high-tech industrial company in managing its IT infrastructure through an as-a-Service model, enabling GE to more easily scale its IT infrastructure across 170 countries. Serving as a catalyst for innovation for more than 125 years, GE is committed to using its leading technology and global reach to deliver solutions that make the world work more efficiently, reliably and safely. Its agreement with Dell is key to delivering on this promise and to create leaner and more autonomous business units. In using an on-premises cloud from Dell Technologies, GE can meet business demand and become more agile by quickly transitioning IT resources without a major reorganization of its infrastructure. The private cloud approach helps GE create a seamless application owner experience with automated provisioning and data services that speeds the deployment of applications and services. GE is using the Dell Technologies APEX portfolio to quickly rebalance workloads across its business units, without creating a significant impact on its businesses and spending.

08:54 EDT American Airlines expects business recovery to continue, accelerate - Says ended quarter with highest liquidity in the company's history. Says carrying far more customers than any other airline. Says has begun deleveraging balance sheet. Says business travel has returned in meaningful way. Says expects business recovery to continue and accelerate. Says expects full business travel recovery in 2022. Says expects international travel recovery to be longer. Says there is pent up demand for international travel. minimal. Comments taken from Q2 earnings conference call.

08:49 EDT Lumen wins $52M U.S. Army Recruiting communications contract - Lumen Technologies recently won a task order to provide secure high-speed connectivity to the U.S. Army Recruiting Command. Lumen's high-speed internet and voice over internet protocol solutions will support the communications needs of Army recruiting sites across the U.S. and in U.S. territories. The 12-year task order, which has an initial term of one year with 11 one-year options, is worth $52M and was awarded under the General Services Administration's 15-year, $50B Enterprise Infrastructure Solutions program.

08:46 EDT Delivery Hero approved by KFTC to extend deadline to divest Yogiyo - Delivery Hero SE announced that it has received the approval from the Korea Fair Trade Commission, or KFTC, to extend the period of implementation of the remedial order requesting Delivery Hero to divest all its shares in Delivery Hero Korea LLC, or "Yogiyo," by August 2, 2021 for another five months. The divestiture is therefore now required to take place by January 2, 2022. "Delivery Hero is currently negotiating the divestiture. The remaining process will continue to be fully compliant with the applicable contractual terms and regulations, as well as the remedies required by the KFTC," the company stated. Reference Link

08:46 EDT Quisitive gets Microsoft Adoption and Change Managment Advanced Specialization - Quisitive Technology Solutions announced that it has received the Microsoft Adoption and Change Management Advanced Specialization. The company said, "The Adoption and Change Management Advanced Specialization is a prestigious status that is only granted to select Microsoft partners who demonstrate deep knowledge, extensive experience, and proven success driving Microsoft 365 adoption, ongoing usage, and organizational change. In order to be eligible, partners must meet a number of strict technical and change management certification requirements and provide detailed customer references that prove execution. This specialization allows partners to further differentiate their organizations, demonstrate their capabilities, and build stronger connections with customers."

08:42 EDT Ageagle Aerial Systems' new CEO issues formal operational update - AgEagle Aerial Systems issued a formal operational update from the company's new Chief Executive Officer, Brandon Torres Declet. Torres Declet stated: "I have recently completed my first 60-days as CEO of AgEagle, during which time I have largely focused my time and energy on thoughtfully evaluating: our company's overarching business model and long-term strategic vision; our technologies, services and new product development roadmaps; strengths and gaps within our existing infrastructure and day-to-day operations; our underpinning values and culture; and the unique and collective skillsets of our coast-to-coast team of professionals. Much of this process was guided by my intent to best align all AgEagle stakeholders to drive toward a common, tangible set of goals... Earlier this week, our leadership team met in Seattle to finalize a strategic plan that we believe will provide for measurable growth of AgEagle's business in the second half of 2021 and into 2022. Central to our plan is aligning our team, capital and focus on near- and mid-term organic revenue growth opportunities within the following sectors: agriculture, energy, construction and government, where adoption of drone solutions is gaining material traction...Given my privilege to serve on both the FAA's Drone Advisory Committee and its Beyond Visual Line of Sight Advisory and Rulemaking Committee, we have a critical seat at the table that should enable AgEagle to help support and define the rapidly changing regulatory environment involving integration of unmanned aerial systems into the U.S. airspace."

08:41 EDT D.R. Horton expects constraints on supply chain to ultimately subside

08:40 EDT Tortoise Acquisition Corp. II partners with StreetLight for EV charging solution - Tortoise Acquisition Corp. II's combination agreement partner Volta Industries, a provider of commerce-centric electric vehicle - EV - charging networks, announced a strategic partnership with StreetLight Data, a provider of big data analytics for mobility, to use their combined analytics for the intelligent deployment of EV infrastructure. The partnership is intended to spur public sector agencies, utilities, transportation planners and engineering firms, among others, to accelerate EV adoption through Volta's PredictEV SaaS solution and StreetLight's mobility data. Volta Charging and Tortoise Acquisition Corp. II entered into a business combination agreement in February subject to customary closing conditions, under which the combined entity will be named Volta and remain on the NYSE under the new ticker symbol "VLTA". PredictEV is a machine-learning tool that helps utilities, municipalities and companies predict electric vehicle adoption and demand for EV charging. Through this partnership, Volta Charging will provide its PredictEV tool to StreetLight customers. StreetLight will also provide Volta Charging with opportunities to expand its market footprint across the U.S. through increased collaboration with transportation planners, engineering firms and public agencies focused on transportation electrification.

08:39 EDT D.R. Horton expects Q4 net sales orders to be lower than Q3

08:37 EDT Daxor announces non-government distribution agreement with Concordance - Daxor announces that it has signed a non-government distribution agreement with Concordance Healthcare Solutions. Daxor and Concordance will work together to provide Daxor's BVA-100 diagnostic blood test to healthcare facilities nationally, driving the use of blood volume measurement to help guide precise, individualized volume management in a wide variety of medical conditions including heart failure and critical care. "Partnering with Concordance will accelerate Daxor's growing sales, allowing our technology to reach even more healthcare systems," said Michael Feldschuh, Daxor's CEO and President. "Combining our sales and marketing efforts will facilitate awareness, adoption and integration of our much-needed and valuable test into standard of care, leading to better outcomes and improvement of the quality of life for patients."

08:36 EDT Corning expands Corning Gorilla Glass composite products - Corning announced a new category for its scratch-resistant and durable glass composite products, Corning Gorilla Glass with DX and Corning Gorilla Glass with DX+. The application of this technology to mobile device cameras enables professional-grade image capture through a unique combination of advanced optical performance, superior scratch resistance, and durability.

08:34 EDT Waitr Holdings announces new partnership with Boston Market - Waitr Holdings announced a new partnership with Boston Market. Waitr and Bite Squad will begin offering delivery from Boston Market locations across the nation. Boston Market is the latest recognizable national brand to add Waitr and Bite Squad for delivery in 2021. In addition to adding several popular established restaurants to its platform, Waitr has brought new service to a long string of underserved cities and towns this year. "Increasing our restaurant variety and partnering with the top restaurant names in the business is a reflection of our commitment to our customers and the communities we serve," said Carl Grimstad, CEO and Chairman of Waitr. "These moves and many others have also strengthened our market presence in the on-demand delivery sector."

08:34 EDT Genuine Parts raises FY21 free cash flow view to $900M-$1.1B from $700M-$900M - Raises FY21 net cash from operating activities to $1.2B-$1.4B from $1B-$1.2B. Sees FY21 effective tax rate approximately 25% vs. prior view of 24.5%-25.5%.

08:32 EDT GrowGeneration acquires Mendocino Greenhouse and Garden Supply - GrowGeneration acquired Mendocino Greenhouse and Garden Supply, a Northern California-based hydroponic garden center, located in Mendocino, California. Mendocino Greenhouse and Garden Supply serves growers in Northern California's Emerald Triangle, the largest cannabis-producing region in the country. Sales are expected to surpass $8M annually. Founded by Nick Halfacre, Mendocino Greenhouse and Garden Supply has provided Northern California growers with specialty hydroponic supplies and professional horticultural consultation services since 2005.

08:31 EDT LMP Automotive enters acquisition agreement for Kia dealership in Connecticut - LMP Automotive (LMPX) announced its entry into a definitive acquisition agreement for a Kia (HYMTF) dealership in Connecticut, along with the associated real estate. The deal is: expected to close in the fourth quarter of this year; have a purchase price of approximately $2.8M for goodwill and $6.45M for the associated real estate expected to be funded through a combination of cash on LMP's balance sheet and debt financing; and it is expected to add approximately $1.9M in adjusted EBITDA or $0.19 per share in 2022. Sam Tawfik, LMP's Chief Executive Officer, stated, "This acquisition, combined with our previously announced acquisitions, would bring LMP's total franchise and dealership count to 22 and 21, respectively, with consolidated annualized revenue, adjusted EBITDA and adjusted EBITDA per share run rate expected to be approximately $1.2B, $82M, and $7.56, respectively."

08:29 EDT NFI Group's ADL enters supply agreement with Nexport - NFI Group Inc. (NFYEF) announced a supply agreement for NFI subsidiary Alexander Dennis Limited to provide a range of zero-emission buses to the Australian market. Under the agreement, Nexport, an Australian owned supplier and producer of electric buses, will assemble bodies from the ADL Enviro family on a BYD (BYDDF) chassis for the local Australian transit market. Nexport will also lead the customer sales and service relationship. ADL and BYD's electric vehicle partnership has been a great success in the UK, Ireland and New Zealand, where they have delivered and taken orders for more than 1,000 battery-electric vehicles and clocked over 30 million miles of zero-emission service. The supply agreement will bring a range of new locally-assembled electric bus products that are currently not available to local bus operators in Australia. The first buses are targeted to be on the road in early 2022 with volume production to be underway by the end of that year.

08:26 EDT VistaGen Therapeutics appoints Maggie FitzPatrick to board of directors - VistaGen Therapeutics (VTGN) announced the appointment of Maggie FitzPatrick to its Board of Directors, replacing Dr. Brian Underdown who recently retired from the Board. Recently, she served as a member of the Exelon Corporation (EXC) executive committee. At Exelon, she led communications, customer engagement, digital and crisis reputation management and philanthropy for the Fortune 100 Company.

08:21 EDT Catalyst Biosciences announce first patient screened for CFI deficiency in study - Catalyst Biosciences announced the screening of the first patient in its CFI-deficiency study in the CB 4332 program, its wholly-owned, first-in-class, enhanced Complement Factor I, intended for prophylactic subcutaneous administration in individuals with CFI deficiency. "The findings from the CFI deficiency screening and natural history of disease studies will be instrumental in identifying patients for the Phase 1/2 trial of CB 4332, planned for mid-year 2022," said Nassim Usman, Ph.D., president and chief executive officer of Catalyst. "Following the disease manifestations and biomarkers of this complement disorder will be important in unlocking the full therapeutic potential of CB 4332." The ConFIrm screening study will measure CFI levels and activity in patients who have diseases related to a CFI deficiency and who may potentially benefit from CB 4332 treatment. The ConFIdence natural history of disease study will follow these CFI-deficient subjects, who often present with repetitive bacterial infections, immune-related diseases, and/or glomerulopathies, for clinical biomarkers and safety of current treatments. The findings from these studies will identify opportunities to potentially develop CB 4332 for treatment in multiple indications.

08:20 EDT eFFECTOR Therapeutics doses first patient in Phase 1b trial of zotatifin - eFFECTOR Therapeutics announced that the first patient has been dosed in a Phase 1b trial evaluating zotatifin as an antiviral agent in an outpatient setting for those with mild to moderate COVID-19 disease. This study is sponsored by a $5.0 million cooperative agreement from the Defense Advanced Research Projects Agency and Defense Health Agency and is being conducted in collaboration with the Quantitative Biosciences Institute at University of California, San Francisco. The Phase 1b trial is a double-blind, randomized dose escalation trial in non-hospitalized patients ages 18-65 with mild to moderate COVID-19. Primary endpoints of the study include safety and tolerability of zotatifin in patients with COVID-19. Secondary endpoints include antiviral activity as assessed by mean change in viral load over time and time to viral load undetectability, as well as time to clinical resolution. Zotatifin will initially be administered in two intravenous infusions one week apart. eFFECTOR recently concluded toxicology and pharmacokinetic studies demonstrating comparable exposure and safety between IV and subcutaneous administration of zotatifin and anticipates transitioning to subcutaneous administration, which is more conducive to treatment in an outpatient setting. An independent international study published in Nature and led by Nevan Krogan, Ph.D., professor, Department of Cellular and Molecular Pharmacology and director of the Quantitative Bioscience Institute at UCSF, identified zotatifin's antiviral activity against SARS-CoV-2 in in vitro studies. Subsequent in vitro studies confirmed that zotatifin had selective antiviral activity with approximately 10-fold greater potency than Remdesivir, the current standard of care for treating patients with COVID-19 with an antiviral agent, and more than 100-fold greater potency than AT-511, the free base form of AT-527, an agent currently in Phase 3 development as a direct-acting SARS-CoV-2 antiviral treatment. Further, in vitro studies have shown that zotatifin has potent antiviral activity across all unique coronavirus subtypes tested, including SARS-CoV-2, SARS-CoV-1, MERS-CoV and CoV-229E.

08:18 EDT Ocuphire Pharma announce publication of data on APX3330 in Phase 2 trial - Ocuphire Pharma announced the publication of a commentary article in the Journal of Cellular Signaling featuring its Ref-1 Inhibitor, APX3330, for the treatment of retinal disease. The article is titled "APE1/Ref-1 as a Novel Target for Retinal Disease". Highlights from the APE1/Ref-1 Review Article: Ref-1 protein regulates multiple transcription factors regulating inflammation and angiogenesis; in five Phase 2 studies involving over 300 patients, APX3330 given oral was well tolerated with no significant safety issues identified. No AE was observed in greater than or equal to 5% of patients treated with APX3330. Mild rash and mild diarrhea were observed in 1% of APX3330 treated patients and were thought to be possibly drug-related. The primary endpoint for the ZETA-1 trial is the Early Treatment Diabetic Retinopathy Score diabetic retinopathy severity score. In the PANORAMA study which examined the effect of the anti-VEGF drug EYLEA on DRSS, this primary endpoint was met with significantly more patients responding to treatment compared to placebo after 24 weeks of 2mg dosing intravitreal every 16 weeks. In the mouse L-CNV model, the efficacy of oral APX3330 was similar to EYLEA intravitreal injections. Taken together with the other safety, PK, and preclinical data, this provides a strong rationale for pursuing diabetic retinopathy in the ZETA-1 trial. "With its dual mechanism of action targeting pathogenic inflammation downstream to Ref-1, we believe APX3330 could represent an important new therapeutic approach in addressing a number of ocular conditions, including as a single agent for diabetic retinopathy and as an adjunctive therapy to anti-VEGF in diabetic macular edema, wet age-related macular degeneration, and other retinal diseases," said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. "As our clinical program surrounding Ref-1 inhibition continues to mature, we expect APX3330 to generate more attention ahead of our Phase 2 data readout in diabetic retinopathy anticipated next year."

08:16 EDT Software Acquisition announces special meeting to approve Otonomo combination - Software Acquisition Group announced the special meeting of its stockholders to approve the previously announced business combination with Otonomo Technologies is scheduled to be held on August 12, 2021 at 11:00 a.m. Eastern Time Holders of Software Acquisition Group's shares of Class A common stock and Class B common stock at the close of business on the record date of July 2, 2021 are entitled to notice of the virtual Special Meeting and to vote at the virtual Special Meeting. If the proposals at the Special Meeting are approved, Software Acquisition Group anticipates that the Business Combination will close shortly thereafter, subject to the satisfaction or waiver of all other closing conditions.

08:14 EDT New York Mortgage announces extension of exchange offer - New York Mortgage Trust announced that it has extended the expiration date of its offer to exchange up to $100,000,000 of new 5.75% Senior Notes due 2026 that have been registered under the Securities Act of 1933, as amended, for an equal amount of outstanding unregistered 5.75% Senior Notes due 2026. As a result of the extension, the exchange offer is now scheduled to expire at 5:00 P.M., New York City time, on July 23, 2021, unless further extended. The exchange offer was originally set to expire at 5:00 P.M., New York City time, on July 21, 2021. As of this date, tenders of approximately $98,750,000 aggregate principal amount, or 98.75%, of the Existing Notes have been received pursuant to the exchange offer. Except for the extension of the expiration date, all of the other terms of the exchange offer remain as set forth in the exchange offer prospectus, dated June 21, 2021.

08:14 EDT Alignment Health Plan, ADA partner to promote diabetes education - Alignment Health Plan and the American Diabetes Association have joined forces for a year-long partnership designed to educate the Alignment community around diabetes management and empower both patients and providers with diabetes resources. Central to the agreement is a license to embed ADA's Diabetes Risk Test on the company's website. The 60-second test uses Type 2 diabetes risk factors, including age, gender, family history, blood pressure, physical activities, wellness, race, ethnicity and body mass index. Currently offered in English and Spanish, the test will be featured on the Alignment Health Plan website now through May 31, 2022.

08:12 EDT VolitionRx's Nu.Q featured in two abstracts on COVID-19 severity prediction - VolitionRx has been working with researchers at two NHS Foundation Trusts on two studies in COVID-19 for which abstracts were released at the International Society on Thrombosis and Haemostasis Congress 2021. Volition previously reported preliminary results demonstrating that its Nu.Q NETs assay correlated well with COVID-19 disease severity. The company now reports early-stage data with the same assay showing that results on admission could predict future COVID-19 disease severity and that serial results correlate with disease progression. The Nu.Q NETs biomarker results taken on hospital admission in this study correlated with COVID-19 disease severity and were predictive of whether patients required care in a general ward or organ support in an intensive care ward. The study results also indicated that elevated values of Nu.Q H3.1 could predict poor outcomes in patients admitted to Intensive Care.

08:12 EDT Ballantyne Strong forms committee to evaluate GreenFirst rights - Ballantyne Strong announced that it has designated a special committee of the independent members of its Board of Directors to evaluate actions to be taken with respect to the rights offering currently being conducted by GreenFirst Forest Products, one of Ballantyne Strong's holdings. The special committee, which consists of the four independent members of the Board of Directors, will determine the extent to which Ballantyne Strong will sell rights and /or exercise additional rights beyond the amount it has previously committed to exercise. Kyle Cerminara, Chairman of Ballantyne Strong's Board of Directors, is also a member of GreenFirst's board of directors, and has recused himself from this process. On June 29, 2021, GreenFirst filed a preliminary prospectus to conduct a backstopped rights offering to finance a portion of the purchase price for its previously announced acquisition of a portfolio of forest and paper product assets. GreenFirst shareholders received three rights for each common share held on the record date for the rights offering, with each right entitling the holder to subscribe for a subscription receipt at a price of $1.50 per subscription receipt, with each subscription receipt entitling the holder thereof to receive an additional common share of GreenFirst for no additional consideration at closing. Ballantyne Strong currently holds approximately 7.0 million common shares in GreenFirst, which resulted in the receipt of approximately 21.1 million rights in the rights offering. On April 12, 2021, Ballantyne Strong announced that it had entered a commitment letter with GreenFirst agreeing to exercise a minimum of approximately US$1.6 million in the rights offering.

08:11 EDT Cavco Industries announces expansion to Fort Worth, Texas production facility - Cavco Industries announced the completed expansion of its Palm Harbor Homes production facility in Fort Worth, Texas. The new building, completed in July 2021, allows for six additional stations for tape-and-texture wall production in the facility's main building and adds 22,400 sq. ft. for frame build, frame paint, floor build and decking. The expansion addresses a major market shift based on consumer demand for tape-and-texture walls. "The timing of this expansion to our production footprint could not be better," said Bill Boor, President and Chief Executive Officer at Cavco Industries. "At a time when demand for our homes is very high, we will now be able to build more with an improved capability to respond to changing customer trends. Increasing production capacity, improving working conditions and updating our homes are key to keeping up with the current demand, and this addition checks all the boxes in helping us to achieve that."

08:10 EDT ImmunoPrecise Antibodies reports TATX-03 neutralizes SARS-CoV-2 Delta variant - ImmunoPrecise Antibodies announced new results from its TATX-03 PolyTope Therapy, a four monoclonal antibody cocktail developed for the potential prevention and treatment of SARS-CoV-2, demonstrating potent pseudovirus neutralizing activity against the SARS-CoV-2 Delta variant. The company anticipated viral evolution leading to novel SARS-CoV-2 variants of concern throughout the design of their PolyTope SARS-CoV-2 therapeutic cocktail, aiming to minimize the risk of mutagenic escape. As such, the company continuously validates, and has demonstrated to date, maintained neutralization potency of IPA's multi-antibody cocktail towards SARS-CoV-2 variants of concern. IPA previously announced that TATX-03 demonstrated strong efficacy in reducing viral load in vivo using a hamster challenge model and potently neutralized pseudovirus of Alpha and Beta variants in vitro. Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPA's TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant. Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta variant with the majority showing maintained binding. These results are consistent with previously announced binding data towards other SARS-CoV-2 mutants, including variants of concern Alpha, Beta and Gamma variants. These binding data, combined with the maintained neutralization potency of IPA's TATX-03 to variants of concern, supports the Company's expectation that rationally designed multi-membered antibody cocktails are more sustainable, e.g. will be functionally less prone to escape-by-one mutations.

08:09 EDT Nisun International announces strategic collaboration with - Nisun International announced Fanlunke Supply Chain Management, a subsidiary of Fintech Shanghai Digital Technology and a controlled affiliate of the company, has signed a cooperation agreement with Beijing Digital Telecom, a subsidiary of state-owned enterprise Zhuhai Huafa Group. The two parties will cooperate in the areas of retail supply chain management services, retail business innovation, and technological innovation. Dixintong is China's largest retail chain for mobile phones and accessories. The two parties will cooperate in supply chain management services to improve the efficiency and safety of the upstream and downstream retail consumer supply chain across multiple industries. Through gradual expansion in scale, the two parties will strengthen the cooperation.

08:09 EDT Fifth Third sees FY21 NII down 1%, noninterest income up 7%-8% - Sees noninterest income up 7%-8% or up 8%-9% excluding the TRA impacts. Sees "stable" loans and leases vs. FY20, with noninterest expense up 2%-3%. Sees FY21 net charge-off ratio 20-25bps and an effective tax rate of 22%-23%.

08:08 EDT Bally's Interactive, Sportradar announce five-year U.S. sports betting deal - Sportradar, a global provider of sports betting and sports entertainment products and services, and Bally's Interactive, a division of Bally's that operates the omni-channel provider's sports betting, iGaming, free-to-play, and daily fantasy sports platforms, announced a five-year sports betting partnership. Under the terms of the deal, Sportradar will provide Bally's Interactive with access to its complete pre-match betting services, live betting services, and content solutions portfolio. Bally's Interactive will incorporate that data portfolio as part of its ambitious expansion plans to become a leader in the North American sports betting markets.

08:07 EDT Electric Last Mile files patent application for EV crash protection system - Electric Last Mile Solutions announcedthat it has filed a provisional patent with the United States Patent and Trademark Office related to the development of its EV crash protection system to improve vehicle and occupant safety and battery stability in the event of a collision. The design encompassed in ELMS' provisional patent application allows for the hollow channel bumper, crash boxes, tubular supports and ring assembly to crumple in stages upon frontal impact to absorb and redirect the energy to protect the occupant as well as the high voltage battery. ELMS expects to hold its next round of crash tests in August and intends to utilize the energy-absorbing front body vehicle assembly design in the Urban Delivery, which the Company intends to launch later this year. The ELMS' Urban Delivery is expected to be the first Class 1 commercial electric vehicle available in the U.S. market and will be produced at the Company's 675,000 square foot plant in Mishawaka, Indiana.

08:06 EDT Reservoir invests in Outdustry, terms not disclosed - Reservoir (RSVR) announces the expansion of its relationship with Outdustry, China's leading music rights and marketing services company. The deal sees Reservoir investing as a minority partner in Outdustry to build on its successes in China and India and extend its strategy to other emerging music markets. The companies have also formed a joint venture to sign and develop Chinese artists and songwriters, plus acquire local music catalogs. Reservoir's investment in Outdustry will enable the companies to capture more value from high-growth territories by building on Outdustry's unique capabilities in directly monetizing complex music markets as well as its market-leading A&R and marketing work. With direct deals at all major Chinese music services, relationships with the local talent industry, and the infrastructure to administer rights themselves, Outdustry has created its own ecosystem to monetize the hundreds of millions of newly digital music consumers in the region. This new investment builds on an existing sub-publishing partnership, announced in June 2020, in which Outdustry Songs became the exclusive sub-publisher in China for Reservoir's roster of songwriters and international catalog of contemporary and long-standing copyrights. Since this agreement, Reservoir has seen triple-digit percentage increases in collections from the territory. This news comes following the announcement that Reservoir has entered into an agreement with Roth CH II (ROCC), a special purpose acquisition company, taking the first step toward becoming a publicly traded company listed on the Nasdaq.

08:03 EDT NeuroMetrix up another 32% in pre-market after Q2 results - Shares of NeuroMetrix are up another 32% in pre-market trading above $27 per share after yesterday's 107% gain. The company reported Q2 results earlier today and also remains in the top-three spots in terms of StockTwits message volume this morning.

08:02 EDT Playstudios, Bowlero announces loyalty marketing program partnership - Yesterday, playAWARDS, the loyalty marketing program created by mobile game developer Playstudios (MYPS), announced it partnering with Bowlero (BOWL) to offer players "one-of-a-kind complimentary and discounted real-world rewards experiences." The companies said: "Players of PLAYSTUDIOS free-to-play mobile apps can now exchange loyalty points earned during gameplay for Bowlero rewards that include a complimentary game of bowling for two and discounted arcade cards at more than 300 Bowlero Lanes, Bowlmor Lanes, and AMF Lanes locations across the country."

07:49 EDT CalAmp's LoJack Italia and Koelliker partner for EV protection - CalAmp's subsidiary, LoJack Italia, has partnered with the Koelliker Group, an importer and seller of electric, connected and intelligent vehicles across Italy. Through the partnership, all new Maxus eDELIVER 3 and eDELIVER 9 electric native light commercial vehicles distributed in Italy by the Koelliker Group, will be pre-installed with LoJack Connect connected car intelligence and services. The LoJack Connect app serves as a virtual assistant by giving MAXUS eDELIVER 3 and eDELIVER 9 drivers greater visibility into kilometers traveled, route monitoring and departure/arrival notifications on a specific location such as a corporate office or delivery location. Access to real-time alerts about the charge level of the 12-volt battery will help protect the control unit and avoid blackouts. The Driving Style feature provides drivers with a score indicating their driving behavior based on an analysis of telematics data. In the event of a collision, CrashBoxx crash response services deliver real-time crash notification to loved ones and immediate assistance to the motorist from LoJack's 24/7 Security Operations Center.

07:46 EDT Marathon Gold reports latest Berry drill results - Marathon Gold is pleased to report the latest assay results from ongoing in-fill drilling at the 1.5 kilometre long Berry Deposit located at the Valentine Gold Project in central Newfoundland, and provide a general update on ongoing exploration activities. The results released represent fire assay data from the first twenty diamond drill holes completed at Berry upon the recommencement of drilling in May after the annual spring break. The Company recently released the first mineral resource estimate for Berry. These latest holes represent in-fill drilling within less delineated hanging-wall portions of the deposit, and in the connecting area between the northeastern and southwestern resource pit shells. Highlights include: VL-21-1010 intersected 5.59 g/t Au over 21 metres including 41.43 g/t Au over 2 metres, and 1.58 g/t Au over 26 metres including 10.22 g/t Au over 1 metre; VL-21-1015 intersected 2.07 g/t Au over 37 metres including 11.78 g/t Au over 1 metre; VL-21-1023 intersected 2.08 g/t Au over 14 metres, and 2.32 g/t Au over 10 metres; VL-21-1020 intersected 0.86 g/t Au over 32 metres, and 0.74 g/t Au over 12 metres, and 1.41 g/t Au over 12 metres; VL-21-1007 intersected 4.16 g/t Au over 5 metres including 12.19 g/t Au over 1 metre, and 1.34 g/t Au over 10 metres, and; VL-21-1021 intersected 2.27 g/t Au over 13 metres. The results released today are derived from seven drillholes located between sections 13488E and 13650E at the western end of the Berry Deposit, and thirteen drillholes located between sections and 14080E and 14590E, close to, or within, the connecting area between the two conceptual pit shells utilized in the April 2021 Berry Mineral Resource Estimate. Gold mineralization at the Valentine Gold Project is contained predominantly within shallowly southwest dipping, en-echelon stacked Quartz-Tourmaline-Pyrite-Gold veins. At the Leprechaun, Marathon and Berry Deposits, these QTP-Au veins form densely stacked and northwest plunging "Main Zone" envelopes within intrusive host rocks on the hanging wall side of the Valentine Lake Shear Zone. The extent of mineralization appears related to the size and frequency of sheared mafic dykes which extend northeast-southwest within the hanging wall, parallel to the shear zone. Eleven of the twenty holes were oriented on a southeast azimuth towards the footwall contact with the VLSZ to test for mineralization at progressive distances into the Berry Deposit's hanging-wall rocks. Nine of the twenty holes were oriented steeply down to the northwest testing for Main Zone type stacked QTP-Au mineralization, either close to the VLSZ or within the hanging-wall. Nineteen of the twenty drill hole returned "significant" drill intercepts of greater than 0.7 g/t Au, and all twenty returned intercepts with gold grades above the 0.3 g/t Au cut-off used in the April 2021 Berry Mineral Resource Estimate.

07:44 EDT Parsons awarded $26M task order to enhance USAF all-domain operations - Parsons has won a task order award worth $26M on the Global Application Research, Development, Engineering, and Maintenance, or GARDEM, indefinite delivery/indefinite quantity contract from the Air Force Research Laboratory. The task order contract has a one-year base period with three option years and will support functional and technical requirements on the GARDEM software baselines for U.S. Air Force and other Department of Defense and Intelligence Community customers. This award is the fifth competitive bid the company has won on the GARDEM contract since 2019, totaling $144M, making Parsons the number one awardee on this IDIQ vehicle. Parsons will perform functional onsite, training, demonstrations, enhancements, modifications, integration, testing, deployments and maintenance of technologies. GARDEM is a $427M contract ceiling vehicle with a mission to create and implement updated software baselines, allowing federal customers across all domains to assess critical information from multiple data sources.

07:42 EDT Thryv expands offering by launching free online tools for small businesses - Thryv Holdings has expanded its offering by launching free online tools for growing small business owners. Thryv built and launched a suite of new free tools to help new start-up small businesses with the essential tools needed to run a successful business. Thryv's latest release features an easy-to-use Invoice Generator, similar to the functionality found in Thryv's subscription platform. This free tool allows business owners to input a few details, as well as their logo, and download a professional, customized invoice in just minutes. They can then email or text this invoice to their customer when requesting payment. Another free tool launched by Thryv is the Google Review Link Generator, which creates a customized link for businesses to send to customers. The tool answers the growing question many small business owners have, "What can I use to request more online reviews?" Thryv's most popular free tool is its Online Experience Scan. Since September 2019, more than 200,000 businesses have used this free scan to find out how their business scores, utilizing Thryv's proprietary client experience index. Businesses using this tool receive scores on their online presence on a scaleof 0-100, based on online listings, ratings and reviews, customer sentiment, website, social media and more. The results also include tips and guidance for improving those scores.

07:40 EDT Flora Growth to relocate headquarters to Miami by 2022 - Flora Growth announced that after conducting a review process the company plans to relocate its headquarters to Miami, Florida by Q1 2022. The company has narrowed down its search to Miami's downtown core, specifically the Brickell financial district. The new location is expected to be larger than its current office space in Toronto, Ontario.

07:40 EDT Huazhu says Q2 RevPAR for Legacy-Huazhu business recovered 102% of 2019 - Huazhu Group announced preliminary results for hotel operations in the second quarter ended June 30, 2021. The company said, "For our Legacy-Huazhu business, the RevPAR in 2Q2021 recovered to 102% of 2019, slightly below our previous expectation. RevPAR recovery in June achieved 100%, slowing down from 106% in May. It was mainly due to COVID-19 resurgence in Guangdong Province and traffic control in Beijing for the celebration of centenary of the Communist Party of China since late May. However, if excluding the impact of Guangdong Province and Beijing, our RevPAR recovery was on track. In July, with the COVID-19 resurgence in Guangdong effectively contained and relaxation of travel restriction in Beijing, our RevPAR recovery resumed. Steigenberger Hotels AG and its subsidiaries saw an initial recovery of hotel demand along with vaccination process in Germany since the first lockdown in November 2020. As of July 16th, 2021, almost 60% of Germans have received at least one shot of vaccine. In July, the recovery continued with occupancy rate reaching 35%. But the recovery is still uncertain given that the recent news shows there is possibly another upcoming wave of delta variant of COVID-19 resurgence in European countries."

07:38 EDT ArcelorMittal invests $25M in Form Energy - ArcelorMittal announces it has completed its second investment in the Company's recently launched XCarb innovation fund, serving as lead investor in Form Energy's $200 million Series D financing round, with a $25 million equity injection. Form Energy, which was founded in 2017 is working to accelerate the development of its breakthrough low-cost energy storage technology to enable a reliable, secure, and fully-renewable electric grid year-round. It has recently unveiled a new iron-air battery which is: low-cost; has multi-day reliability; scalable; and can be sited anywhere. Alongside the $25 million investment, ArcelorMittal and Form Energy have signed a joint development agreement to explore the potential for ArcelorMittal to provide iron, tailored to specific requirements, to Form Energy as the iron input into their battery technology.

07:36 EDT MarketWise begins trading on Nasdaq - MarketWise debuts on The Nasdaq Global Market under the ticker symbol "MKTW." Formerly known as Beacon Street Group, the business combination with Ascendant Digital Acquisition Corp. (ACND), a special purpose acquisition company, was approved by Ascendant shareholders on July 20, 2021 with approximately 85.5% of the vote in favor of the business combination and closed on July 21, 2021. Alongside its public company debut, MarketWise has also launched a new website www.marketwise.com and brand identity, which showcases the breadth and quality of its product offerings. Trading is expected to begin on the Nasdaq today, under the new ticker symbol "MKTW" for MarketWise's Class A common stock and "MKTW W" for MarketWise's warrants.

07:35 EDT Veritone trading resumes

07:33 EDT Domino's Pizza announces new $1B share repurchase program - Subsequent to the end of the second quarter, on July 20, the company's Board of Directors authorized a new share repurchase program to repurchase up to $1B of the company's common stock. This repurchase program replaces the company's previously approved $1B share repurchase program, which was fully utilized in connection with the ASR Agreement.

07:31 EDT Renalytix AI appoints Joseph Hutson Vice President Global Quality, Regulation - Renalytix announced the appointment of Joseph Hutson as its Vice President of Quality and Regulatory. Hutson brings 23 years of experience in the life sciences industry. He will lead teams focused on assuring compliance with United States and international Quality Management System regulations and standards and driving efficient approval for a series of products under the KidneyIntelX brand through review by the appropriate regulatory authorities including the United States Food and Drug Administration and the European Medicines Agency, and other country specific regulatory bodies. Most recently, at Abbott Molecular Diagnostics, Hutson led Quality, Global and Clinical Compliance and he played a role in the rapid development, FDA Emergency Use Authorizations, manufacturing scale up and global distribution of 50M COVID-19 diagnostic tests throughout the world.

07:28 EDT Glatfelter to acquire Jacob Holm for an enterprise value of $308M - Glatfelter announced that it has entered into a definitive agreement to acquire Jacob Holm, a global leading manufacturer of spunlace nonwoven fabrics for cleaning, high-performance materials, personal care, hygiene and medical applications, for an enterprise value of approximately $308M including the extinguishment of debt and subject to post-closing adjustments. With the acquisition of Jacob Holm, Glatfelter will acquire four additional manufacturing facilities and six sales offices located in the Americas, Europe, and Asia, and approximately 800 employees world-wide. Jacob Holm's broad product offerings and blue-chip customer base will expand Glatfelter's portfolio to include surgical drapes and gowns, wound care, face masks, facial wipes and cosmetic masks. The acquisition of Jacob Holm's Sontara business, a leading brand of finished products for critical cleaning wipes and medical apparel, will also enhance Glatfelter's technological capabilities. "Today's announcement represents another significant step forward in Glatfelter's transformation. The combination of Jacob Holm's quality spunlace and advanced fiber products along with Glatfelter's industry-leading airlaid and composite fibers products will provide a best-in-class suite of nonwovens technologies, applications, and expertise to serve customers' growing global demand. By acquiring Jacob Holm, we will further diversify our nonwovens and substrate offerings and enhance our overall innovation capabilities," said Dante Parrini, Chairman and CEO of Glatfelter. The transaction is subject to the satisfaction of customary closing conditions, including receipt of required regulatory clearances, and is expected to be completed later this year.

07:27 EDT Biogen says FDA approval of ADUHELM based on thorough analysis of data - A letter from Biogen Head of Research and Development, Alfred Sandrock read in part, "On June 7, 2021, ADUHELM became the first approved treatment to address a defining pathology of Alzheimer's disease: targeting the reduction of amyloid plaques in the brain. We believe patients, family members and physicians deserve the facts about the therapy and the process by which it was approved so they may make informed decisions...Unfortunately, ADUHELM's approval has been the subject of extensive misinformation and misunderstanding. It is normal for scientists and clinicians to discuss data from experiments and clinical trials, to debate, and to disagree, on the interpretation of data. That is how science advances and we welcome these discussions. Recently, however, there has been a turn outside the boundaries of legitimate scientific deliberation. We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab. A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients. A step toward such transparency is to correct some of the misinformation we have seen...Several people have stated that all previously studied anti-amyloid antibodies clear amyloid from the brain but have failed as a class to demonstrate benefit. This is factually incorrect. First generation anti-amyloid antibodies were not specific for aggregated forms of amyloid beta, or targeted soluble monomeric amyloid beta, or were deficient in effector function. As a result, these antibodies do not clear amyloid from the brain. As such, there is no basis for using the failure of these antibodies as a reason to question the approval of ADUHELM. The review process that led to accelerated approval was extensive and thorough, during which we responded to numerous questions and requests from the FDA. The approval is supported by data of more than 3,000 patients and 2.2 million pages of clinical data and analyses. Separately, we have seen statements that all of ADUHELM's results are "post hoc" - in other words, that a filter was applied after the fact to interpret the data in a certain way. That is also factually incorrect. The primary and secondary endpoints had been pre-specified in the Phase 3 trial protocols, before the first patient was enrolled into the trials. The ADUHELM label shows the results on these pre-specified endpoints, based on data that had already been collected at the sites by the time the trials were prematurely terminated on March 21, 2019. Safety data were also extensively reviewed and are well documented in the label, so that physicians can make informed benefit-risk decisions and take appropriate actions as they monitor their patients under treatment....The FDA's decision to approve ADUHELM to treat patients with Alzheimer's disease was based on thorough analysis of the data...The FDA also stated: "Although the ADUHELM data are complicated with respect to its clinical benefits, FDA has determined that there is substantial evidence that ADUHELM reduces amyloid beta plaques in the brain and that the reduction in these plaques is reasonably likely to predict important benefits to patients."1 The FDA also shared that it "is requiring Biogen to conduct a post-approval clinical trial to verify the drug's clinical benefit." In the announcement of its decision to approve ADUHELM through its Accelerated Approval pathway, the FDA explained the rigor underlying its analysis: "We examined the clinical trial findings with a fine-tooth comb, we solicited input from the Peripheral and Central Nervous System Drugs Advisory Committee, we listened to the perspectives of the patient community, and we reviewed all relevant data. We ultimately decided to use the Accelerated Approval pathway-a pathway intended to provide earlier access to potentially valuable therapies for patients with serious diseases where there is an unmet need, and where there is an expectation of clinical benefit despite some residual uncertainty regarding that benefit. In determining that the application met the requirements for Accelerated Approval, the Agency concluded that the benefits of ADUHELM for patients with Alzheimer's disease outweighed the risks of the therapy."..The approval of ADUHELM has already renewed investment activity in Alzheimer's disease research and development, and we are optimistic that other innovative treatments will soon join ADUHELM."

07:25 EDT Lexaria summarizes antiviral drug studies and ongoing strategy - Lexaria Bioscience reviews its 2021 antiviral drug program to date and summarize expected next steps. Lexaria's objectives in its 2021 antiviral drug examination program thus far have been to determine whether: DehydraTECH processing of compounds from leading classes of antiviral drugs for SARS-CoV-2/COVID-19, HIV/AIDS and other infectious diseases could exhibit evidence of superior oral absorption relative to controls, DehydraTECH processing of those compounds would preserve expected viral inhibitory performance upon efficacy testing in infected mammalian cells, and DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities that could be challenging to guide through the regulatory approval process. All three of these objectives have been met. Lexaria has successfully tested and published summary results on five compounds from three antiviral drug classes, and in each of these drug classes has evidenced significant gains with up to a three-fold increase in oral drug delivery into the bloodstream upon animal testing when processed with DehydraTECH:

07:23 EDT Flyht Aerospace announces closing of oversubscribed private placement - FLYHT Aerospace Solutions reported that the Company has closed its previously announced non-brokered private placement issuing 8,828,818 common shares at an issue price of $0.75 per Common Share resulting in proceeds to the Company of CAD$6,621,615. Directors, officers and senior employees contributed 10% of the Offering total. The Company intends to use the proceeds from the Offering to fund FLYHT's growth initiatives including potential strategic acquisitions, to repay in full the outstanding debentures due on July 24, 2021, and general corporate purposes. With the closing of this Offering, a new insider of the Company was created who now controls greater than 10% of the Common Shares of FLYHT. All of the Common Shares issued pursuant to the Offering are subject to a four month hold period. Completion of the Offering is subject to the final approval of the TSX Venture Exchange.

07:22 EDT Plus Therapeutics treats first patient in latest dosing in ReSPECT-GBM trial - Plus Therapeutics announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT-GBM clinical trial for recurrent glioblastoma has been successfully treated. The present cohort implements a 40% increase in volume and total radioactivity from the previous cohort. "The ReSPECT(TM)-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile," said Marc Hedrick M.D., President and CEO of Plus Therapeutics. "We plan to provide an update on the trial in the fourth quarter of 2021." Twenty-two patients across eight dosing cohorts have been treated in the ReSPECT trial to date. Thus far, no treatment emergent dose-limiting toxicities have been observed, despite absorbed radiation doses to the tumor of up to 740 Gray.

07:21 EDT Else Nutrition expands into Rouses Markets locations - ELSE NUTRITION announces that it will be expanding into Rouses Markets retail locations. Family owned and operated since 1960, Rouses Markets employs approximately 7,000 people and operates 65 full-service supermarkets in Louisiana, Mississippi and Alabama.

07:19 EDT XPO Logistics appoints Karlis Kirsis as CLO for GXO Logistics spin-off - XPO Logistics announced that Karlis Kirsis has been appointed chief legal officer for GXO Logistics, Inc., the intended spin-off of XPO's logistics business. Kirsis currently serves as senior vice president, European chief legal officer for XPO Logistics Europe. He will be responsible for GXO's legal and compliance functions, including corporate governance, litigation and commercial matters. As previously announced, XPO expects to spin off its logistics business as a separate, publicly traded company on August 2, 2021. As the largest pure-play contract logistics provider in the world, GXO will be well-positioned to capitalize on the big three secular tailwinds of e-commerce growth, customer demand for logistics automation and the burgeoning trend toward supply chain outsourcing. The business currently includes approximately 885 logistics locations in 27 countries.

07:18 EDT Tilt Holdings appoints Dana Arvidson as COO - TILT Holdings announced the appointment of Dana Arvidson as COO. In this newly created role, Mr. Arvidson will work closely with TILT's senior management team to drive operational and financial growth across the Company's core businesses. As TILT's COO, Mr. Arvidson will provide operational leadership for the Company's strategic objectives and establish KPIs to gauge efficiency and effectiveness of internal and external operational processes. In partnership with Chief Financial Officer Brad Hoch, Mr. Arvidson will be responsible for delivering strong results across sales, profitability and market expansion. Most recently, Mr. Arvidson served as Vice President of Corporate Development for PhyNet Dermatology.

07:17 EDT Versus Systems announces partnership with Military Bowl Foundation - Versus Systems announced a strategic partnership with the Military Bowl Foundation, Inc. to power technology behind interactive experiences for live events and digital activations. The Military Bowl presented by Peraton, benefiting the USO, is the National Capital Region's college football postseason bowl game featuring a matchup between teams from the Atlantic Coast Conference and the American Athletic Conference.

07:16 EDT Coty appoints Constantin Sklavenitis as chief prestige brands officer. - Coty announced the appointment of Constantin Sklavenitis to the role of chief prestige brands officer. Sklavenitis will take up the role on September 6. Sklavenitis joins Coty from MAC Cosmetics where he was senior VP/GM of North America. Reporting to the CEO, Sue Nabi, Sklavenitis will be overseeing all prestige brands. He will be responsible for one of Coty's strategic growth pillars, namely to become a key player in Prestige make-up and expand on skincare.

07:15 EDT Global Blood Therapeutics submits sNDA to FDA for Oxbryta - Global Blood Therapeutics announced updates across several of its development programs in sickle cell disease. The company has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval for Oxbryta for the treatment of SCD in children ages 4 to 11 years, together with a related separate New Drug Application required to seek approval for a pediatric weight-based formulation of Oxbryta. Additionally, GBT initiated two global, randomized, placebo-controlled, pivotal Phase 3 clinical trials of inclacumab, a novel P-selectin inhibitor. The company also enrolled the first SCD patient in a Phase 1 study evaluating GBT021601, a next-generation hemoglobin S polymerization inhibitor, in people with SCD. The Oxbryta pediatric sNDA and NDA include data from the open-label Phase 2a HOPE-KIDS 1 Study. An analysis of data presented at the European Hematology Association 2021 Virtual Congress in 45 children with SCD ages 4 to 11 years enrolled in the study showed that weight-based treatment with Oxbryta resulted in rapid and sustained improvements in hemoglobin. Concurrent improvements in markers of hemolysis also were observed. GBT requested priority review for the sNDA and NDA, which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the sNDA and the NDA are complete and acceptable for filing.

07:12 EDT Arvinas, Pfizer announce collaboration to develop, commercialize ARV-471 - Arvinas (ARVN) and Pfizer (PFE) announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is currently in a Phase 2 dose expansion clinical trial for the treatment of patients with estrogen receptor positive / human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer. Under the terms of the agreement, Pfizer will pay Arvinas $650M upfront. Separately, Pfizer will make a $350 million equity investment in Arvinas. The companies will equally share worldwide development costs, commercialization expenses, and profits. ER is the primary driver of hormone receptor positive breast cancer, which is the most common breast cancer subtype. Endocrine therapy is a backbone of ER+ breast cancer treatment and is used as monotherapy or as combination therapy as a standard of care across treatment settings. Arvinas and Pfizer are seeking to develop ARV-471 as the potential endocrine therapy of choice for patients and their physicians. Interim data presented in December 2020 from the ongoing Phase 1 dose escalation clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer indicated its potential as a novel oral ER targeted therapy. This study has enrolled heavily pretreated patients, with all patients having received prior treatment with cyclin-dependent kinase 4/6 inhibitors. Despite the advanced stage of disease and heavy pretreatment, these interim data, as of December 2020, demonstrated that ARV-471 can promote substantial ER degradation and exhibits an encouraging clinical efficacy and tolerability profile. ARV-471 currently is being evaluated as a treatment for metastatic breast cancer in a Phase 1 dose escalation study, a Phase 1b combination study with Pfizer's IBRANCE and a Phase 2 monotherapy dose expansion study. Arvinas and Pfizer expect to initiate two additional trials of ARV-471 in 2021, including a second Phase 1b combination trial with everolimus and a trial in the neoadjuvant setting. In 2022, Arvinas and Pfizer expect to initiate Phase 3 studies across lines of therapy in metastatic breast cancer, including combinations with IBRANCE, followed by pivotal studies in the early breast cancer setting. The two companies had previously announced in 2018 a separate research collaboration and license agreement for the discovery and development of drug candidates using Arvinas' PROTAC technology. The agreement is a worldwide co-development and co-commercialization collaboration. ARV-471 is wholly owned by Arvinas and under the financial terms of the agreement, Pfizer will pay Arvinas $650 million upfront. Separately, Pfizer will invest $350 million in Arvinas, receiving approximately 3.5 million newly issued shares of Arvinas common stock, priced at a 30% premium to the 30-day volume weighted average price on July 20, 2021. This represents an equity ownership stake by Pfizer of approximately 7%. Arvinas is also eligible to receive up to $400 million in approval milestones and up to $1 billion in commercial milestones, in addition to sharing profits on ARV-471 worldwide. Arvinas and Pfizer will jointly develop ARV-471 through a robust clinical program designed to position ARV-471 as an endocrine backbone therapy of choice across the breast cancer treatment paradigm, from the adjuvant setting through late-line metastatic disease. Closing of the equity investment agreement is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S., and other customary closing conditions.

07:10 EDT Biogen sees using part of $3.55B remaining share buyback authorization in 2021 - Biogen said: "This guidance continues to reflect our expectation that both Non-GAAP R&D and Non-GAAP SG&A expenses will be higher in the second half of the year than they were in the first half due to collaborations, program readouts, and investments in ADUHELM. We expect that we will utilize a portion of the remaining share repurchase authorization of $3,550 million throughout 2021."

07:07 EDT American Airlines expects to reduce debt by over $15B by end of 2025 - American is committed to improving its balance sheet. The Company now expects to reduce its debt by more than $15 billion by the end of 2025 versus its previous guidance of $8 billion to $10 billion. American plans to accomplish this objective through naturally occurring amortization, by using excess cash and free cash flow to pay down prepayable debt, and by potentially using cash instead of debt for certain future aircraft deliveries. As evidence of the Company's commitment to delever and its confidence in the future, today American is prepaying the entirety of its $950 million spare parts term loan that was scheduled to mature in April 2023.

07:06 EDT Newmont sees FY21 gold production 6.5M ounces - Sees FY21 other metal production 1.3M ounces.

07:02 EDT International Game to deploy cashless lottery technology for Washington - International Game announced that its subsidiary, IGT Global Solutions, has extended its lottery gaming systems contract to deploy next-generation cashless lottery technology for Washington's Lottery, making Washington the seventh U.S. state to leverage IGT's cashless lottery solutions. This agreement extends IGT's current contract through June 30, 2029.

06:57 EDT Jefferson Energy executes terminal services contract with Exxon Mobil - Jefferson Energy Companies, a subsidiary of Fortress Transportation and Infrastructure Investors (FTAI), is pleased to announce it has entered into a new contract to expand terminal services to ExxonMobil Oil, a wholly owned subsidiary of Exxon Mobil(XOM). Jefferson Energy is constructing approximately 1.9M barrels of new storage capacity at the Jefferson Energy terminal and five connecting pipelines between the ExxonMobil Beaumont refinery and Jefferson Energy terminal that will increase utilization of its existing marine infrastructure. The engineering and construction has begun for this second phase of the Jefferson Energy terminal master plan buildout and will increase total storage to approximately 6.2M barrels.

06:54 EDT Southwest reports Q2 economic fuel costs $1.92 per gallon vs. $1.33 last year - Southwest (LUV) said, "The Company's second quarter 2021 available seat miles (ASMs, or capacity) per gallon (fuel efficiency) declined 8.7 percent, year-over-year, due to the return to service of more of its least fuel-efficient aircraft, the Boeing (BA) 737-700. When compared with second quarter 2019, fuel efficiency improved 4.5 percent in second quarter 2021 due to the March 2021 return to service of its most fuel-efficient aircraft, the MAX. The MAX is critical to the Company's efforts to modernize its fleet, reduce carbon emissions intensity, and achieve carbon neutrality by 2050. The Company expects third quarter 2021 fuel efficiency to be in line with second quarter 2021, on a nominal basis."

06:52 EDT Reliance Steel raises existing share repurchase program to $1B

06:42 EDT AT&T reports Q2 2.8M total domestic HBO Max, HBO subscriber net adds - WarnerMedia: 2.8 million total domestic HBO Max and HBO subscriber net adds; total domestic subscribers of 47.0 million, up 10.7 million in past year; and 67.5 million7 globally, up 12.0 million in past year. Launched ad-supported HBO Max and international offerings. Domestic HBO Max and HBO subscriber ARPU of $11.90. Total revenues up 30.7% to $8.8 billion. Direct-to-Consumer subscription revenues up nearly 40%. Now expect 70-73 million global HBO Max/HBO subscribers by end of year.

06:40 EDT AT&T CEO says 'pleased with our performance and our momentum is strong' - "We're pleased with our performance and our momentum is strong," said John Stankey, AT&T CEO. "For the fourth consecutive quarter, we saw good subscriber growth across wireless, fiber and HBO Max. Mobility delivered strong service revenue, EBITDA and postpaid phone growth. Our fiber business, which leads on customer satisfaction, grew subscribers and penetration. HBO Max had another strong quarter and is ahead of plan to be a leading direct-to-consumer streaming platform, with both subscriber- and ad-supported choices. As a result, we're raising our global HBO Max year-end forecast to 70 million to 73 million subscribers. Also, we're updating full-year guidance for consolidated revenue, wireless service revenue, adjusted EPS and free cash flow."

06:39 EDT Fifth Third reports Q2 net interest margin 2.63% vs. 2.75% a year ago

06:37 EDT AT&T raises FY21 free cash flow view to $27B range from $26B range

06:34 EDT D.R. Horton: Housing market conditions remain 'very robust' - Donald R. Horton, Chairman of the Board, said, "The D.R. Horton team delivered outstanding results in the third fiscal quarter of 2021, highlighted by EPS increasing 78% to $3.06 per diluted share. Our consolidated pre-tax income increased 81% to $1.4 billion on a 35% increase in revenues to $7.3 billion and a 490 basis point increase in our pre-tax profit margin to 19.4%. These results reflect our experienced teams and production capabilities, industry-leading market share, broad geographic footprint and diverse product offerings across multiple brands. Housing market conditions remain very robust, with homebuyer demand exceeding our current capacity to deliver homes across all of our markets. As our top priority is to consistently fulfill our commitments to our homebuyers, we have slowed our home sales pace to more closely align to our current production levels, while building out the infrastructure needed to support a higher level of home starts. We are also selling homes later in the construction cycle when we can better ensure the certainty of the home close date for our homebuyers. After starting 22,600 homes during the quarter, our homes in inventory at June 30, 2021 increased 44% from a year ago to 47,300 homes, positioning us to finish fiscal 2021 strong and produce double-digit volume growth in fiscal 2022."

06:33 EDT AT&T reports Q2 789,000 postpaid phone net adds - Mobility: 789,000 postpaid phone net adds; 1,156,000 postpaid net adds; 174,000 prepaid phone net adds; Postpaid phone churn of 0.69%, equaling lowest churn ever; Revenues up 10.4%; service revenues up 5.0%; equipment revenues up 31.9%; Operating income of $6.0 billion, up 3.4% year over year; EBITDA4 up 2.7%; Operating income margin of 31.7%; EBITDA service margin 55.9%.

06:30 EDT AT&T reports Q2 cash from operations $10.9B - Cash from operating activities in the second quarter was $10.9B, down $1.1B when compared to 2020, reflecting increased cash spend for content and taxes. Total cash paid for WarnerMedia's content investment in the second quarter was $5.3B ($2.4B higher than the prior-year comparable period). Capital expenditures in the second quarter were $4B, and when including $1.3B cash paid for vendor financing, gross capital investment was $5.3B.

06:27 EDT OneMain Holdings sees FY21 operating expense growth of 5%-7% - Comments taken from Q2 earnings conference call presentation slides.

06:18 EDT Precision Drilling sees 2021 CapEx $63M - 2021 CapEx includes $41M for sustaining, infrastructure and intangibles and $22M for expansion and upgrades. Expects that the $63M will be split $59M in the Contract Drilling Services segment, $3M in the Completion and Production Services segment and $1M to the Corporate segment. At June 30, Precision had capital commitments of $127M with payments expected through 2023.

06:11 EDT Baozun signs LOI with Cainiao - Baozun announced that Baozun and its wholly-owned subsidiary, Baotong, have signed a letter of intent with Cainiao for its equity investment in Baotong, Baozun's warehousing and fulfillment solution subsidiary. Baozun, Baotong and Cainiao have also entered into a Letter of Intent of Business Cooperation Agreement to further explore and develop brand e-commerce opportunities. The company believes Cainiao's Investment in Baotong will help the company to accelerate its pace to capture growing opportunities in China's e-commerce industry. The completion of the Investment will enable the company to leverage Cainiao's national logistics expertise and technology to greatly improve its cost structure and enrich its service portfolio. Concurrently, Baozun, Baotong and Cainiao have entered into the LOI of BCA, pursuant to which the parties will cooperate to develop competitive solutions in customized, high-value and digitalized logistics services. Baotong may also provide operational and technological management and consulting services, to Cainiao's broader customer base.

06:09 EDT Gap announces launch of new integrated Rewards program - Gap announced the launch of a new integrated Rewards program across the U.S. and Puerto Rico: One Membership. Four Brands. The new program will simplify and streamline how members can earn and redeem their rewards within our four brands by combining the previous credit card and loyalty programs under Navyist Rewards, Gap Good Rewards, Banana Republic Rewards, and Athleta Rewards. With membership levels, the new program will make it easier for both Cardmembers and Rewards members to earn points, enable them to redeem their rewards faster and create opportunities to give back by donating to one of our five charitable funds. Rewards members receive special perks, bonuses, and brand exclusive benefits when they join. And as part of the program, members can shop across all four brands and no matter which brand they enrolled in or how they spend, all of their points will be in one place.

06:05 EDT TRI Pointe expects to deliver 1,450-1,550 homes in Q3 - For the third quarter, the company anticipates delivering between 1,450 and 1,550 homes at an average sales price between $620,000 and $630,000. The company expects its homebuilding gross margin percentage will be in the range of 23.5% to 24.5% for the third quarter and anticipates its SG&A expense as a percentage of home sales revenue will be in the range of 9.5% to 10.0%. Lastly, the company expects its effective tax rate for the third quarter will be approximately 25.0%.

06:04 EDT TRI Pointe raises share repurchase authorization by $250M - The company announced that its Board of Directors has authorized the repurchase of up to an additional $250M of common stock under its existing stock repurchase program and extended the term of the Repurchase Program through December 31, 2022, increasing the aggregate authorization under the Repurchase Program from $250M to $500M.

05:18 EDT Buyer consortium extends deadline for Hollysys shareholders to submit consents - The buyer consortium consisting of Shao Baiqing, Ace Lead Profits and CPE Funds Management announced the extension of the deadline by which shareholders of Hollysys may submit consents to the consortium's proposed resolutions concerning its proposed acquisition of all outstanding ordinary shares of the Company not already owned by the Consortium at a price of $17.10 per share in cash. The Company's shareholders are now asked to sign, date and return the white consent card or otherwise submit their consents as soon as possible, but in any event on or before August 20. The decision to extend the deadline for submitting consents is primarily prompted by inquiries from shareholders who wish to know the outcome of the ongoing litigation before the British Virgin Islands Court concerning the legality of the company's amendments to its memorandum and articles of association, passed by the company's board of directors and without shareholders' approval, on January 7. As the court has not handed down its judgment, the consortium will extend the deadline for submission to August 20, which may be further extended if the court judgment for this litigation is not available at that time. In further response to shareholder inquiries, the consortium states the following regarding the company's July 15 press release: "The Consortium is aware of the press release by the Company on July 15, 2021, with the misleading title "HollySys Sets Record Straight on Consortium's Consent Solicitation" (the "July 15 Press Release"). We do not agree with the July 15 Press Release. It should be noted that many of the issues raised in the July 15 Press Release are currently being scrutinised before the Court, and the Consortium believes that the July 15 Press Release is disrespectful to the Court whilst it deliberates on the proceedings, and irresponsible and misleading to the Company's shareholders. Accordingly, and to show the necessary respect to the Court as any sensible persons should, it is the Consortium's decision not to make any further comment on the July 15 Press Release until judgment is handed down by the Court. Once a judgment is handed down, the Consortium will make an announcement for the purpose of, among other things, responding to the July 15 Press Release."

05:11 EDT 51job purchases new Shanghai corporate headquarters for RMB 2.07B - 51job announced that it has entered into an agreement to purchase an office building in Shanghai, which will serve as its new corporate headquarters. The building is part of the Crystal Plaza complex, which is located in the Qiantan area of Pudong District. The total floor area is approximately 32,400 square meters. The purchase price is estimated to be RMB 2.07B, which will be funded by the company's existing cash resources and debt financing. The company anticipates moving into the new premises in 2022.